This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problems Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 239/12, 407/12, 239/42, 207/22, 223/12, C07C 279/14, C07D 213/81, 213/82, 307/68, C07C 275/16, C07D 403/12, A61K 31/505, 31/41, 31/155, 31/17

(11) International Publication Number:

WO 99/52879

(43) International Publication Date:

21 October 1999 (21.10.99)

(21) International Application Number:

PCT/US99/08180

A1

(22) International Filing Date:

14 April 1999 (14.04.99)

(30) Priority Data:

09/059.579

14 April 1998 (14.04.98) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPO-RATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: KEES, Kenneth, Lewis; 147 Finney Road, Glenmoore, PA 19343 (US). GARRICK, Lloyd, Michael; 117 Mill Grove Drive, Norristown, PA 19403 (US). GOPAL-SAMY, Ariamala; 1106 Devon Court, Mahwah, NJ 07430

(74) Agents: BARRETT, Rebecca, R.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive. Parsippany, NJ 07054 (US) et al.

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS

$$R^1$$
 R^2
 R^3
 R^5
 R^5
 R^5
 R^5

(57) Abstract

Compounds of formula (I) are useful in the treatment of various disorders including, but not limited to, cancer, angiogenesis, restenosis, inflammation, bone diseases, and as antiviral agents. Novel methods of makings compounds of formula (I) are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece .		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	Œ	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	(L	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	LS	Iceland	MW	Malawi	US	United States of America
CA	Canada	ſΤ	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		2311020 110
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
RR	Estonia	LR	Liberia	SG	Singapore		

-1-

ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS

5

10

15

20

25

Background of Invention

The integrin $\alpha_{\nu}\beta_{3}$ has been shown to mediate the invasion of cancerous melanoma cells into healthy tissue (Sefton et al., Proc. Natl. Acad. Sci, USA. 1992, 89, 1557-1561) and to protect these cells against natural cell death cycle (apoptosis) (Montgomery et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 8856-8860). Vitronectin receptor ($\alpha_{\nu}\beta_{3}$) antagonists have been shown to inhibit the growth of various solid tumors of human origin (Brooks et al., Cell, 1994, 79, 1157-1164). More recently, $\alpha_{\nu}\beta_{3}$ has been shown to be involved in liver metastasis (Yun et al., Cancer Res., 1996, 56, 3103-3111).

Although angiogenesis is an important and natural process in growth and wound healing, it is now appreciated that a variety of clinically relevant conditions are pathologically related to these processes, and that the integrin $\alpha_v \beta_3$ is involved. For example, $\alpha_v \beta_3$ was shown to be expressed on human wound tissue but not on normal skin (Brooks, et al., Science, 1994, 264, 569-571) and is preferentially expressed on angiogenic blood vessels, such as those feeding a growing/invading tumor. It has also been shown that antagonists of $\alpha_v \beta_3$ promote tumor regression by inducing apoptosis of the tumor cells (Brooks et al., Cell, 1994, 79, 1157-1164). This process of neovascularization which is critical for tumor growth and metastasis, is also an important event in ocular tissue, leading to diabetic retinopathy, glaucoma and blindness (Adonis et al., Am. J. Ophthal., 1994, 118, 445-450; Hammes et al., Nature Med., 1996, 2,529-533; Friedlander, et al., Natl. Acad. Sci. U.S.A., 1996, 93, 9764-

10

15

25

9769) and in joints, promoting rheumatoid arthritis (Peacock et al., J. Exp. Med., 1992, 175, 1135-1138).

 $\alpha_{\nu}\beta_{3}$ has been shown to play a pivotal role in the proliferation and migration of-smooth muscle and vascular endothelial cells, a pathological process leading to restenosis after balloon angioplasty (Choi et al., J. Vasc. Surgery, 1994, 19, 125-134; Matsumo et al., Circulation, 1994, 90, 2203-2206). At least one type of virus (adenovirus) has been shown to utilize $\alpha_{\nu}\beta_{3}$ for entering host cells (White et al., Current Biology, 1993, 596-599.

Various bone diseases involve bone resorption which is mediated by only one known class of cells, the osteoclasts. When activated for resorption, these motile cells initially bind to bone, a process well known to be mediated by $\alpha_v \beta_3$ (Davies et al., J. Cell. Biol., 1989 109, 1817-1826; Helfrich et al., J Bone Mineral Res., 1992, 7, 335-343). It is also well known that blockade of $\alpha_v \beta_3$ with antibodies or RGD containing peptides block osteoclast cell adhesion and bone resorption *in vitro* (Horton et al., Exp. Cell Res. 1991, 195, 368-375) and that echistatin, an RGD containing protein, inhibits bone resorption *in vivo* (Fisher et al., Endocrinology, 1993, 132, 1411-1413). More recently, an RGD peptidomimetic has likewise been shown to inhibit osteoclasts *in vitro* and, by i.v. administration *in vivo* prevents osteoporosis (Engleman et al., J. Clin. Invest., 1997, 99, 2284-2292).

20 $\alpha_v \beta_3$ also plays an important role in autoimmune diseases such as psoriasis and rheumatoid arthritis. Peacock, et al., supra.

Numerous patents/applications have claimed various non-peptide $\alpha_v\beta_3$ inhibitors for some or all of the above applications (e.g. EP92307157.5A, EP92307156.7A, WO9708145, WO9532710, WO96/00730, WO9637492, WO9626190, WO9606087, WO97/23451, WO9724119, WO9724122, WO9724124, WO96-US20744961220, EP796855, WO9733887, WO97/34865, WO97/35615, WO97/36859, WO97/35615, WO97/08145, US5668159, WO98/08840, WO98/14192).

WO9532710 teaches compounds for inhibiting bone resorption. Among the preferred compounds are compounds having a 4-alkyloxy substituted benzoic acid core coupled to an (α-phenylsulfonylamino-3-amino propanoic acid) terminus. None of the exemplary compounds teach a 2-hydroxy substitution of the benzoyl core. The lead compound of WO9532710 exhibited limited bioavailability *in vivo*. (VnR symposium Abstracts, 211th ACS National Meeting, New Orleans, LA, March 24-28 (1996).)

WO9708145 discloses certain meta-guanidine, urea, thiourea and azacyclic amino substituted benzoic acid derivitaves as integrin antagonists.

European patent application number EP0320032 broadly claims certain 2-aminoalkoxy-substituted pyridazine derivatives. The compounds disclosed do not comprise an acid functionality.

WO9513262 teaches certain 2-hydroxy-4-heteroarylmethoxy benzamide derivatives are endothelin inhibitors.

15

10

5

Detailed Description of the Invention

According to the present invention are provided novel compounds of Formula I:

20 wherein

$$G^{-N}$$
 O
 O
 R^3
 R^3
 R^5
 R^5

G is

5

R¹ and R² are independently, hydrogen, alkyl of 1 to 6 carbon atoms, mono or bicyclic aralkyl of 6 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

R³ is hydrogen, mono or bicyclic aryl of 6 to 10 carbon atoms, 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O;

R⁴ is hydrogen, NHR⁹, OR⁹, NHCO₂R⁹, NHCONHR⁹, NHCOR⁹ or NHSO₂R⁹; provided that R³ and R⁴ are not both hydrogen;

20

15

R⁵ is hydrogen or alkyl of 1 to 6 carbon atoms which may optionally be substituted with a terminal group which serves as a prodrug. For example, the alkyl group may be substituted with an acid, alcohol or amino functionality to form an alkylamino, carboxyalkyl or alkanol group;

25

R⁶ and R⁷ are independently hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or aralkoxy of 6 to 10 carbon atoms:

10

15

20

25

30

R⁸ and R⁹ are independently hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbons, alkynyl of 2 to 10 carbons, mono or polycycloalkyl of 3-12 carbon atoms, mono or polycycloalkyl-alkyl of 4-12 carbon atoms, mono or bicyclic aryl of 6 to 10-carbon atoms, 6 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O, mono or bicyclic aralkyl of 7 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

n is an integer from 1 to 4; and m is 0 or 1; or a pharmaceutically acceptable salt thereof.

In some preferred embodiments of the present invention G is is 6-aminopyridin-2yl, pyridin-2yl, pyrimidyl, tetrahydropyrimidyl, tetrahydropyrimid-4-one, dihydroimidazolyl, amino(imino)-, pyridyl-urea, benzyl-urea, or imidazolidinyl.

In a still more preferred embodiment of the present invention G is 6-amino-pyridin-2-yl, pyridin-2yl, dihydroimidazolyl, 5-amino 1,2,4-triazol-4yl (and/or all tautomers thereof) or tetrahydropyrimidyl, R³ is H, and n is 2 or 3.

In some preferred aspects of the invention R9 is methyl, ethyl, n-propyl. i-propyl, allyl, homoallyl, propargyl, pentyl, n-hexyl, octyl, neopentyl, trichloroethyl, n-butyl, i-butyl, butynyl, phenyl, methylphenyl, dimethylphenyl, halophenyl, methoxyphenyl, acetylphenyl, biphenyl, naphthyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, trimethylcyclopropyl, phenylcyclopropyl, adamantyl, adamantylmethyl, cinnamic, pyridyl or dimethylfuranyl.

"Alkyl", whether used alone or as part of a group such as "alkoxy", means a branched or straight chain having from 1 to 10 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl. Lower alkyl refers to alkyl having from 1 to 4 carbon atoms. Alkyl groups may be substituted.

10

15

20

25

"Cycloalkyl" as used herein refers to mono or polycyclic alkyl groups of 3-12 carbon atoms. Exemplary cycloalkyl groups include cyclopropyl, cyclohexyl and adamantyl. Cycloalkyl groups may be substituted. One preferred substitution is phenyl.

"Aryl" whether used alone or as part of a group such as "aralkyl", means mono or bicyclic aromatic ring having from 6 to 10 carbon atoms. Exemplary aryl groups include phenyl and naphthyl. The aryl may be substituted with one or more substituents. Substituents include halogen, lower alkyl, alkoxy, alkylthio, amino, nitro, cyano, carboxy, carboxyalkyl, alkanoyl, alkylamino, perhaloalkyl, hydroxy, oxy and phenyl. One preferred aryl group is phenyl.

"Heterocycloalkyl" whether used alone or as part of a group such as "heterocycloalkyl-alkyl" means a stable, saturated or unsaturated 5 to 10 membered mono or bicyclic ring having from 1 to 3 heteroatoms selected from N, O and S. Exemplary heterocycloalkyls include pyrazinyl, pyrazolyl, tetrazolyl, furanyl, thienyl, pyridyl, imidazolyl, pyrimidinyl, tetrahydropyrimidinyl, isoxazolyl, thiazolyl, isothiazolyl, quinolinyl, indolyl, isoquinolinyl, oxazolyl and oxadiazolyl. Preferred heteroaryl groups include pyrimidinyl, tetrahydropyrimidinyl, pyridyl, and imidazolyl. Most preferred heteroaryls include pyridin-2yl, and tetrahydropyrimidine. The heteroaryl may also be substituted with one or more substituents. Substituents include halogen, lower alkyl, alkoxy, alkylthio, amino, nitro, cyano, carboxy, carboxyalkyl, alkanoyl, alkylamino, perhaloalkyl, hydroxy, oxy and phenyl. Preferred substituents include amino and oxy. Preferred substituted heterocycloalkyls include 6 aminopyridin-2yl and tetrahydropyrimid-4-one.

"Aralkyl" means an aryl-alkyl group in which the aryl and alkyl are as previously described. Exemplary aralkyl groups include benzyl and phenethyl. Use in this context, the alkyl group may include one or more double bonds.

"Heterocycloalkyl-alkyl" means an heterocycloalkyl group in which the heterocycloalkyl and alkyl are as previously described. Use in this context, the alkyl group may include one or more double bonds. Exemplary heterocycloalkyl-alkyls

10

15

20

30

include pyridylmethyl, pyridylethyl, thienylethyl, thienylmethyl, indolylmethyl, and furylmethyl.

"Alkoxy" means an alkyl-O group in which the alkyl group is as previously. described. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, n-butoxy, and t-butoxy.

"Aralkoxy" means an aryl-alkoxy group in which aryl and alkoxy are as previously described.

"Halogen" includes fluorine, chlorine, iodine and bromine.

"Prodrug", as used herein means a compound which is convertible *in vivo* by metabolic means (e.g. by hydrolysis) to a compound of Formula I.

NMR and IR spectra indicate the 2-hydroxy substitution of Formula I is strongly H-bonded to the adjacent carbonyl, effectively forming a six-membered ring which conformationally restricts the amide residue bearing the carboxy terminus. Thus, the 2- hydroxy substitution of the phenyl core of Formula I plays a significant role in integrin receptor selectivity.

In addition, the 2-hydroxy compounds of the invention are believed to obviate at least two of the three hydrating water molecules which are known to form intermolecular hydrogen bonds with secondary amide functionalities. The energy needed to desolvate water molecules for efficient transport across cell membranes is thus reduced in compounds of the present invention and is believed to contribute to the markedly improved plasma concentrations seen with compounds of the present invention.

Preferred compounds include:

- 25 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid,
 - (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid,

25

- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,
- 5 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
- 20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(butoxycarbonyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 35 (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(hexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid,
- (2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

25

- (2S)-2-{[(1-adamantylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 5 (2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid,
- 20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 35 (2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-(isobutyrylamino)propanoic acid,

25

- (2S)-2-(hexanoylamino)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 5 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-(pentanoylamino)propanoic acid,
 - (2S)-2-[(3,3-dimethylbutanoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-[(cyclohexylcarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid,
- 20 (2S)-2-[(2-cyclohexylacetyl)amino]-3-({2-hydroxy-4-[2-(1,4.5.6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid,
 - (2S)-2-[(2-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methylbenzoyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid,
- 35 (2S)-2-[(4-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid,
- (2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

25

- (2S)-2-[(2-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 5 (2S)-2-[(4-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid
 - (2S)-2-[(2,3-dimethylbenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-[(3-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(phenoxycarbonyl)amino]propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid,
- 20 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyphenoxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,
- (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,
- 35 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(4-nitrobenzyl)oxy]carbonyl}amino)propanoic acid,
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,

25

- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methylphenoxy)carbonyl]amino}propanoic acid,
- 5 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid,
 - (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid,
- 20 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(tert-butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid,
- 35 (2S)-2-{[(2-ethylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-2-{[(2,4-dichloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid,

25

- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid,
- 5 (2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethyl)anilino]carbonyl}amino)propanoic acid,
- 20 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid,
 - $(2S)-2-\{[(4-chloroanilino)carbonyl]amino\}-3-(\{2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl\}amino)propanoic acid,$
 - (2S)-2-{[(4-fluoroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-({[4-(ethoxycarbonyl)anilino]carbonyl}amino)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 35 (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid,

25

- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octylamino)carbonyl]amino}propanoic acid,
- 5 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(ethoxycarbonyl)amino]propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,
- 20 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(hexyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,
- 35 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
 - (2S)-2-[(butoxycarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy}-2-hydroxybenzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.
- (2S)-2-{[(butylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

25

- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(hexylamino)carbonyl]amino}propanoic acid,
- 5 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(allylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
- (2S)-2-{[(benzylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - 3-({4-[2-(2,5-dihydro-1H-imidazol-4-ylamino)ethoxy]-2-hydroxybenzoyl)amino)-N-{[(1S, 2R)-2-phenylcyclopropyl]amino)carbonyl)alanine,
- 20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid,
 - (2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-(isobutyrylamino)propanoic acid,
 - (2S)-2-(butyrylamino)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
- 35 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(hexanoylamino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pentanoylamino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3,3-dimethylbutanoyl)amino]propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2,2,3,3-tetramethylcyclopropyl)-carbonyl]amino}propanoic acid,

25

- (2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
- 5 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-arnino)-2-(pent-4-ynoylamino)propanoic acid,
 - (2S)-2-[(cyclohexylcarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid,
 - (2S)-2-[(2-cyclohexylacetyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
- 20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid,
 - (2S)-2-[(2-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-methylbenzoyl)amino]propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2-methoxybenzoyl)amino]propanoic acid,
 - (2S)-2-[(4-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
- 35 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid,
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid,
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-arnino)-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid,
- (2S)-2-[(2-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

25

- (2S)-2-[(4-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy}-2-hydroxybenzoyl}amino)propanoic acid,
- 5 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,3-dimethylbenzoyl)amino]propanoic acid,
 - (2S)-2-[(3-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid,
 - (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 20 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
- 35 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,

25

- (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,
- 5 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}- amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(propoxycarbonyl)amino]propanoic acid,$
- 20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid,
 - $(2S)-2-\{[(allyloxy)carbonyl]amino\}-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}propanoic acid,$
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,
- 35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[arnino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[([1,1'-biphenyl]-2-ylmethoxy)carbonyl]amino}propanoic acid,

25

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(4-bromobenzyl)oxy]carbonyl}amino)propanoic acid,
- 5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(4-fluorobenzyl)oxy]carbonyl}amino)propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(2-bromobenzyl)oxy]carbonyl}amino)propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[({[4-(trifluoromethyl)benzyl]oxy}carbonyl)amino]propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-toluidinocarbonyl)amino]propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-\{[(2-methoxyanilino)carbonyl]amino\}propanoic acid,$
- 20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-chloroanilino)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-bromoanilino)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-toluidinocarbonyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid,
- 35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-chloroanilino)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-fluoroanilino)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}-ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(cyclohexylamino)carbonyl]amino}propanoic acid

25

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid,
- 5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzylamino)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(octylamino)carbonyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(anilinocarbonyl)amino]propanoic acid,$
- 20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isobutyrylamino)propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino}-2-(butyrylamino)propanoic acid,$
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(hexanoylamino)propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-30 (pentanoylamino)propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3,3-dimethylbutanoyl)amino]propanoic acid,
- 35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid,
 - (2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-{[4-(2-{[amino(imino)methyl]-amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pent-4-ynoylamino)propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-((cyclohexylcarbonyl)amino]propanoic acid,

- $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(2-phenylacetyl)amino]propanoic acid,$
- 5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-phenylpropanoyl)amino]propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(2-cyclohexylacetyl)amino]propanoic acid,$
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-chlorobenzoyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methylbenzoyl)amino]propanoic acid,
- 20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxybenzoyl)amino]propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(4-chlorobenzoyl)amino]propanoic acid,$
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methylbenzoyl)amino]propanoic acid,
- (2S)-3-[[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxybenzoyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(pyridin-3-ylcarbonyl)amino]propanoic acid,
- 35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isonicotinoylamino)propanoic acid,
 - $\label{lem:condition} \end{cases} $$ (2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino}-2-\{(2,5-dimethyl-3-furoyl)amino]propanoic acid,$
- 40
 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-bromobenzoyl)amino]propanoic acid,
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-bromobenzoyl)amino]propanoic acid,

WO 99/52879 PCT/US99/08180

-22-

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,3-dimethylbenzoyl)amino]propanoic acid,
- 5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-chlorobenzoyl)amino]propanoic acid,
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-(benzoylamino)propanoic acid,$
- 10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-ethylbenzoyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-butoxybenzoyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid,
- 25 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid,
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid,
- (2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[(benzylamino)carbonyl]amino}-ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
- 40 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(octyloxy)carbonyl]amino}propanoic acid,

15

- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid,
- 10 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isobutoxycarbonyl)amino]propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid,
- (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid,
- 25 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
- 40 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,

- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,
- (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]-carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,
- 10 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid,
 - (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-20 ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,
- 25 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid,
- (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,
- 40 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,

- (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-5 ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methylbenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
- 10 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methoxybenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(4-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(4-{2-[({[4-(dimethylamino)benzyl]amino}-carbonyl)amino]ethoxy}-2-hydroxybenzoyl)amino]propanoic acid,
- (2S)-3-[(4-{2-[({[4-(aminosulfonyl)benzyl]amino}carbonyl)amino]ethoxy}-2hydroxybenzoyl)amino]-2-{[(benzyloxy)carbonyl]amino}propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2-hydroxy-4-{2-[({[4-(trifluoromethoxy)-benzyl]amino}carbonyl)amino]ethoxy}benzoyl)amino]propanoic acid,
- 25 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(2-methylbenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2-bromobenzyl)amino]-carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2,4-dichlorobenzyl)amino}carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,
 - (2S)-3-({4-[2-({[(2-aminobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid,
- 40 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-2-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,
 - (2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid,

- (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid tert-butyl ester,
- (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(pyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid,
 - 3-{2-Hydroxy-5-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxylbenzoylamino)-3-phenyl-propionic acid ethyl ester,
- 10 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid 2-(2-tert-butoxy-carbonylamino-ethoxy)-ethyl ester,
- (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid ethyl ester,
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino}-propionic acid,
- 3-{2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino}-3-phenyl-propionic acid,
 - (2S)-2-{Adamantan-1-yloxycarbonylamino)-3-{2-hydroxy-4-[2-(1,4.5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino)-propionic acid,
 - (2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid ethyl ester,
- 3-{2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy)-benzoylamino)-3-phenyl-propionic acid ethyl ester,
 - (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxyl]-benzoylamino}-propionic acid,
- 35 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid isopropyl ester,
 - (2S)-2-tert-Butoxycarbonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid,
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid,

- 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester,
- 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid,
- 5 2(S)-Benzenesulfonylamino-3-[2-hydroxy- 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride,
 - 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydrochloride,
 - 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride,
 - 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride,
 - 3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride,
- 3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid hydrochloride,
 - 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester,
- 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-20 yl-propanoic acid,
 - 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester dihydro-chloride,
 - 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid,
- 25 3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid ethyl ester dihydrochloride,

- 3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid,
- 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl-amino]-3-phenyl-propanoic acid ethyl ester,
- 5 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl-amino]-3-phenyl-propanoic acid hydrochloride,
 - 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]-benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride,
- 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-phenyl-propanoic acid,
 - 3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino]-3-phenyl-propanoic acid ethyl ester,
 - 3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino]-3-phenyl-propanoic acid,
- 3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride,
 - 3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]-benzoylamino]-3-phenyl-propanoic,
- 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydro-chloride,
 - 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid methyl ester,
 - 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid,
- 25 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-methyl-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid, and

WO 99/52879 PCT/US99/08180

2-Amino-3-[2-hydroxy-4-[2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid dihydrochloride, or pharmaceutical salts thereof.

It is understood that the definition of compounds of Formula (I) include racemates, (racemic mixtures) and individual enantiomers or diastereomers. All asymmetric forms, individual isomers and combinations thereof are within the scope of the present invention.

5

10

15

25

30

Optically active isomers may be prepared, for example by resolving the racemic mixtures. The resolution can be carried out by methods known to those skilled in the art such as in the presence of resolving agent, by chiral chromatography, or combinations thereof.

Compounds of Formula I are useful in methods of selectively inhibiting or antagonizing an integrin receptor such as avb3. More specifically, methods of the present invention include but are not limited to methods of inhibiting cancer (tumor metastasis, tumorgenesis/tumor growth), angiogenesis (as in cancer, diabetic retinopathy, rheumatoid arthritis), restenosis (following balloon angioplasty or stent implantation), inflammation (as in rheumatoid arthritis, psoriasis), bone diseases (osteopenia induced by bone matastases, immobilization and glucocortocoid treatment, periodontal disease, hyperparathyroidism and rheumatoid arthritis), and viral infection by administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

The compounds of this invention are prepared in accordance with the solid phase combinatorial library synthesis methods or solution phase synthesis methods.

Generally, to prepare the compounds via combinatorial methodology, the starting acylresorcinol ester is condensed with an alkylene chain bearing a terminal primary amino group which is suitably blocked/protected. Methods for this condensation include, but are not limited to selective alkylation of one (the non-H-bonded hydroxyl group) of the resorcinol hydroxy groups, using standard procedures such as the Gabriel synthesis (Angew Chem. Int. Ed. Engl. 7, 1968, 919-930 (1968) or Mitsunobu reaction (Synthesis, 1981,1-28). After conventional deprotection of the N-

10

15

terminus and the acid, the amine 2-2 was protected as fluorenylmethyloxy carbamate (Fmoc) 2-6. On the other hand, in the case of G = pyrimidine 2-3, the primary amine 2-2 was activated with trimethylsilyl chloride in the presence of 2-bromopyrimidine in refluxing (anhydrous) 1, 4-dioxane. The carboxylic acid 2-3 was activated as pentafluorophenyl ester 2-5. The carboxylic acid 2-3 was also hydrogenated under catalytic hydrogenation conditions to obtain the tetrahydropyrimidine derivative 2-4.

Orthogonally protected 2,3-diamino propionic acid 1-1 was used for carboxylic acid terminus and was immobilized on polymer support with linkers like but not limited to Wang. The 2-amino group of the 2,3-diaminopropionic acid was Fmoc protected, while the 3- amino group was dde (4,4-dimethyl-2,6-dioxocyclohex-1-ylideneethyl) protected. The 2-amino group was deprotected and further derivatized to 1-4, 1-5, 1-6 and 1-7 using various acylating agents including but not limited to chloroformates, isocyanates, sulfonyl chlorides, carboxylic acids/chlorides. The 3-amino group was deprotected to give 1-8, 1-9, 1-10 and 1-11 and coupled with the resorcinol acid derivatives 2-4, 2-5 or 2-6.

N-terminus derivatives such as dihydroimidazole 5-3, azepine 5-4, guanidine 6-3, and ureas 6-4 were prepared from common primary amine intermediate 4-2.

Schemes 1-6, below, demonstrate the solid phase synthesis practice of this invention as it relates to the examples specified. Detailed synthetic procedures for representative compounds of this invention follow.

Throughout the Examples data for LC (@254 nM) were obtained under the following conditions. HP 1100, 23oC, 10µL injected; Column: YMC-ODS-A 4.6 x 50 5µ;

25 Gradient A: 0.05% TFA/Water, B: 0.05% TFA/Acetonitrile Time 0 & 1 min: 98%A &2%B; 7 min: 10%A & 90%B; 8 min: 10%A & 90%B; 8.9 min: 98%A & 2%B; Post time 1 min; Flow rate 2.5 mL min.; Detection: 215 and 254 nm, DAD.

2(S)-(Fluorenylmethyloxycarbonyl)amino-3-(4,4-dimethyl-2,6dioxocylohex-1-ylideneethyl)aminopropionic Acid on Wang Resin (1-2)

Wang resin (Wang, S. J. Am. Chem. Soc. 1973, 95, 1328-1333) (Advanced ChemTech 200-400 mesh, 1% crosslinked; loading: 0.92 mmol/g; 5g, 4.6 mmol) was swollen in N,N-dimethylformamide (DMF) (20 mL). A solution of N-a-fmoc-N-b-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-diaminopropionic acid 1-1 (Fmoc-Dpr(Dde)-OH) (Nova Biochem) (4.513g; 9.2 mmol) in DMF (30mL) was treated with N-hydroxybenzotriazole (HOBT) (1.242g; 9.2 mmol), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (3.487g; 9.2 mmol) and N,N-diisopropylethylamine (DIEA) (3.2 mL; 18.4 mmol) and added to the resin. The mixture was shaken at room temperature for 8 h. The mixture was filtered and the resin was washed with DMF (3 x 40mL), methanol (MeOH) (3 x 40mL) and dichloromethane (DCM) (3x 40mL). The resin was dried in vacuo to give 6.956g. Resin Loading: 0.8 mmol/g.

2-Amino-3-(4,4-dimethyl-2,6-dioxocylohex-1-ylideneethyl)aminopropionic Acid on Wang Resin (1-3)

The resin 1-2 (6.956 g) in DMF was treated with 20% piperidine in DMF (40mL) for 10 min and filtered. Another 40mL portion of 20% piperidine in DMF was added to the resin and shaken at room temperature for 20 min. The resin was filtered and washed with DMF (3 x 40mL), MeOH (3 x 40mL) and DCM (3 x 40mL). The resin (1-3) was dried in vacuo.

25 <u>2(S)-(2,2-Dimethyl-propoxycarbonylamino)-3-(4,4-dimethyl-2,6-dioxocylohex-1-ylideneethyl)amino-propionic acid on Wang Resin (1-4)</u>

The resin 1-3 (925 mg; 0.75 mmol) was swollen in dichloromethane and treated with diisopropylethylamine (969 mg; 1.3 mL; 7.5 mmol) followed by neopentyl

10

15

chloroformate (451.8 mg; 3mmol). The reaction mixture was shaken at room temperature using orbital shaker (Thermolyne RotoMix Type 50800) for 18 h. The mixture were filtered and the resin was washed with dichloromethane (4 x 4 mL), methanol (4 x mL) and dichloromethane (2 x 4 mL). The resins was dried under vacuum. A sample of the was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

A sample of the resin was removed and subjected to cleavage with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. The product was characterized by HPLC: 4.28 min (82% @ 220 nm); MS: 383 (M+H)⁺.

The above reaction conditions were applied for synthesis of urea 1-5 and sulfonamide 1-6, using phenyl isocyanate and phenyl sulfonyl chloride, respectively, in the place of neopentyl chloroformate.

A number of chloroformates, isocyanates and sulfonyl chlorides were used in the above reaction.

20

25

2(S)-benzoylamino-3-(4,4-dimethyl-2,6-dioxocylohex-1-ylideneethyl)amino-propionic acid on Wang Resin (1-7)

The resin 1-3 (925 mg; 0.75 mmol) was washed with DMF to swell the resin. A solution of benzoic acid (183 mg; 1.5mmole) in DMF was mixed with diisopropylcarbodiimide (192 mg; 0.25 mmole), hydroxybenzotriazole (228 mg; 1.5 mmole) and dimethylaminopyridine (18 mg; 1.5 mmole) and the mixture was added to the resin. The reaction mixture was shaken at room temperature for 16h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol

(4 x mL) and dichloromethane (4 x 4 mL). The resulting resin 1-7 was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

5

10

15

20

Alternately, carboxylic acids were used in the above reaction in the place of benzoic acid.

3-Amino-2(S)-(2,2-dimethyl-propoxycarbonylamino)-propionic acid on Wang Resin (1-8)

The resin 1-4 was shaken with a solution of 2% hydrazine in dimethylformamide (3mL) for 5 min. at room temperature. The reaction mixture was filtered and an additional 3 mL of a solution of 2% hydrazine in dimethylformamide was added and the reaction mixture was shaken at room temperature for 5 min. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test for the presence of free amine (resin turns blue).

A sample of the resin was removed and subjected to cleavage with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. The product was characterized by HPLC: 4.686 min (78% @ 220 nm); MS m/z 219 (M+H)⁺.

Resin bound compounds 1-5, 1-6 and 1-7 were subjected to similar deprotection condition to afford the free amines 1-9, 1-10 and 1-11 respectively.

-35-

Scheme 2

PCT/US99/08180

Methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate (2-1)

5

10

Methyl 2, 4-dihydroxy benzoate (14.5g, Aldrich), 2-(N-t-butoxycarbonyl)ethanol (13.9g, Aldrich) and triphenyl phosphine (22.6g, Aldrich) were combined in 350 mL of THF and cooled in ice under N₂ atmosphere. Diethyl diazodicarboxylate (DEAD,

15g, Aldrich) was added, the ice bath removed and the reaction mixture allowed to stir at ambient temperature for 15h. The solvent was removed on a rotary evaporator and the residue chromatographed on silica gel (300g, Merck silica 60), elution with CH_2Cl_2 to give 18g of methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate, as a viscous oil. NMR (300 MHz, CDCl₃) δ 11.0 (s, 1 H), 9.5 (d, J = 8Hz, 1H), 6.4 (m, 2H), 5.0 (broad, 1H), 4.0 (t, J = 5Hz, 2H), 3.91 (s, 3H), 3.54 (m, 2H), 1.45 (s, 9H), MS (+ESI) m/z 334 (M+Na)⁺.

4-(2-Aminoethoxy)-2-hydroxybenzoic acid, hydrochloride (2-2)

10

15

20

Ester 2-1 (7.2g) was treated with 5eq. KOH (dissolved in minimum amount of water and equal volume of 1, 4-dioxane) at room temperature until TLC indicated complete absence of starting material (3-12h). The reaction mixture was acidified (pH = 6) with the addition of 1N HCl solution and extracted with ethyl acetate. The extract was washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated on the rotary evaporator. The crude product (5.34g) was recrystallized from ether, then dissolved in 1, 4-dioxane and treated with an excess of anhydrous HCl (4M in dioxane, Aldrich). The mixture was allowed to stand at ambient temperature for 24h. Volatile materials were removed in vacuo on the rotary evaporator to give 2-2 as a hydroscopic off-white solid. NMR (400 MHz, DMSO-d6) δ 13.6 (broad, 1H), 11.6 (broad, 1H), 8.3 (broad, 3H), 7.7 (d, J = 9 Hz, 2H), 6.53 (m, 2H), 4.23 (t, J = 5Hz, 2H), 3.2 (s, broad, 2H).

2-Hydroxy-4-[2-(pyrimidine-2ylamino)ethoxy]benzoic acid (2-3)

25

30

A mixture of compound 2-2 (20g), diissopropylethylamine (DIPEA, 74 mL), trimethylsilylchloride (TMSCl, 21.6 mL) and 2-bromopyrimidine (Lancaster, 13.5g) were combined in 350 mL 1, 4-dioxane at room temperature, then brought to reflux under N₂ atmosphere. After 2 days, an additional 12 mL trimethylsilyl chloride was added, and the mixture continued at reflux for an additional 2 days (until TLC showed

no stating material remained). The reaction mixture was cooled to ambient temperature, concentrated to dryness in vacuo on a rotary evaporator and the residue suspended in water. The heterogeneous mixture was refluxed briefly, allowed to cool to room temperature, the product collected on a vacuum filter and air dried to give 15.3g of 2-3, as a tan powder. NMR (400 MHz, DMSO-d₆) δ 12 (very broad, 2H) 8.3 (d, J = 5 Hz, 2H) 7.7 (d, J = 9Hz, 1H), 7.28 (t, J = 6Hz, 1H), 6.57 (t, J = 5Hz, 1H), 6.49 (m, 2H), 4.13 (t, J = 6Hz, 2H), 3.62 (q, 2H); MS (+ESI) m/z 276 (M+H)⁺; IR (KBr) v (cm⁻¹) 3275, 3000, 1660, 1625.

10 2-Hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2ylamino) ethoxy]-benzoic acid (2-4).

Compound 2-3 (2g) was combined with 10% Pd/C (0.5g), acetic acid (100 mL) and concentrated hydrochloric acid (0.7 mL). The mixture was stirred at room temperature under an atmosphere of H_2 (balloon) for 2 days. Celite was added and the mixture stirred for 0.5h, then filtered through a pad of celite with the aid of isopropanol. Volatile materials were removed on the rotary evaporator and the residue warmed with heptane (~0.5h, 100°C) followed by concentration in vacuo to give 2-4 as a tan foam. NMR (400 MHz, DMSO-d₆) δ 12.9 (broad, 2H), 8.25 (s, broad, 2H), 7.85 (t, J = 6Hz, 1H), 7.66 (d, J = 9 Hz, 1H), 6.48 - 6.41 (m, 2H), 4.07 (t, J = 5Hz, 2H), 3.56 - 3.50 (m, 2H), 3.22 (m, 2H, overlapping with H_2O peak), 1.79 (m, 2H); IR (KBr) n (cm⁻¹) 3450 (broad); MS (+ESI) m/z 280 (M + H)⁺.

2,3,4,5.6-Pentafluorophenyl 2-hydroxy-4-[2-(pyrimidine-2-ylamino)ethoxy]-benzoate (2-5)

25

30

15

20

Acid 2-3 (1.18g; 4.3 mmol) in dioxane (40 mL) was treated with DIEA (1.5 mL; 8.6 mmol) and cooled to 0°C. Pentafluorophenol (3.16g; 17.2 mmol) was added followed by dicyclohexyl carbodiimide. The reaction mixture was allowed to warm to room temperature and stirred for additional 16 h. The solid precipitated was filtered off and the mother liquor was concentrated to dryness and the residue was purified using silica

column chromatography, eluted with 50% ethyl acetate in hexane to give 1.01 g of 2-5 as a white solid. NMR (300 MHz, CDCl3) δ 10.0 (s, 1H), 8.3 (d, J = 5 Hz, 2H) 8.0 (d, J = 9Hz, 1H), 6.57 (t, J = 5Hz, 1H), 6.49 (m, 2H), 5.5 (t, J = 3Hz, 1H), 4.2 (t, J = 6Hz, 2H), 3.9 (q, 2H).

5

10

15

4-[(2-fluorenylmethyloxycarbonylamino)ethoxy]-2-hydroxybenzoic acid (2-6)

The Amino acid **2-2** (1.864g; 8 mmol) was dissolved in 1:1 acetone - water (50 mL) containing sodium carbonate (1.696g; 16 mmol). To the solution was added Fmoc-Osu (2.696 g; 8 mmol) in acetone (25 mL) dropwise at room temperature. The solution was stirred at room temperature for 18 h. The reaction mixture was concentrated and the residue was dissolved in water and extracted with ether (2 x 50 mL). The aqueous layer was cooled in an ice bath and acidified with 6N HCl to pH 3. The solid obtained was filtered and washed with water and dried under vacuo (3.22g). NMR (300 MHz, DMSO-d6) δ 7.9 (d, 2H), 7.65-7.75 (m, 2H), 7.55 (t, 2H), 7.4 (t, 2H), 7.3 (t, 2H), 6.5 (m, 2H), 4.35 (d, 2H), 4.25 (t, 1H), 4.05 (t, 2H), 3.4 (t, 2H).

Scheme 3

Example 1 (2S)-3-{{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (3-2)

5

10

15

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy|benzoy|}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (3-1)

The resin 1-8 (100mg) was washed with DMF to swell the resin. A solution of 2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoic acid 2-4 (70 mg; 0.25mmole) in DMF was mixed with diisopropylcarbodiimide (32 mg; 0.25 mmole), hydroxybenzotriazole (38mg; 0.25 mmole) and dimethylaminopyridine (3 mg; 0.025 mmole) and the mixture was added to the resin. The reaction mixture was shaken at room temperature for 16h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resulting resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

The resin 3-1 was treated with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 3-2 was purified via preparative HPLC. NMR (400MHz, MeOH-d4) δ 7.7 (d, J = 7 Hz, 1H), 6.5 (m, 2H), 4.45 (q, 1H), 4.1 (t, 2H), 3.8 - 3.65 (m, 4H), 3.55 (t, 2H), 3.35 (t, 4H), 2.0 (m, 2H), 0.9 (s,

9H).

HR-MS FAB m/z for $C_{22}H_{33}N_5O_7$ calcd. 480.2458 (M⁺+1), obsd. 480.2431.

WO 99/52879

The following compounds were synthesized as described in the above Scheme 3 (Path A), using various resin bound carbamates in the place of (1-8). These compounds were characterized using LC and MS as shown in Table 1.

- 5 Example 2
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid.
- Example 3
 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.
- Example 4
 (2S)-3-([2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.
- Example 5
 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.
- Example 6
 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.
- Example 7
 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.
- Example 8
 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.
- Example 9
 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

-42-

Example 10

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

5

Example 11

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-[(butoxycarbonyl)amino]propanoic acid.

10

Example 12

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

15

Example 13

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

20

Example 14

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Table 1

Ex.	R9	LC @ 254 nm	(M+H)*	Ex.	R9	LC @ 254 nm	(M+H)*
2	Methyl	2.92 min	424	8	n-Hexyl	4.12 min	494
3	Ethyl	3.09 min	438	9	n-Octyl	4.62 min	522
4	n-Propyl	3.30 min	452	1	(CH3)3CCH2	3.77 min	480
5	i-Propyl	3.28 min	452	10	(CCI3)3CCH2	3.81 min	542
6	Allyl	3.21 min	450	11	n-Butyl	3.60 min	466
7	Homoallyl	3.46 min	463	12	i-Butyl	3.58 min	466
13	Propargyl	3.18 min	448	14	Benzyl	3.74 min	500

The following compounds were synthesized as described in the above Scheme 3, (Path A) using various resin linked ureas 1-9 in the place of carbamate (1-8). These compounds were characterized using LC and MS as shown in Table 2.

Example 15

(2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

10

Example 16

(2S)-2-{[(hexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

15 Example 17

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid.

Example 18

20 (2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

-44-

Example 19

(2S)-2-{[(1-adamantylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 20

(2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 21

10 (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 22

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 23

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid.

Example 24

20

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid.

25 Example 25

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid.

Example 26

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid.

Example 27

(2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 28

(2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 29

(2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

35

Example 30

(2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 31

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid.

Example 32

10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid.

Table 2

Ex.	R9	LC @ 254 nm	T 12.2				
Ex.	RG	LC @ 234 lbli	(M+H)*	Ex.	R9	LC @ 254	(M+H) ⁺
<u></u>	<u> </u>					nm	1
15	нзс~~	3.30 min	465	24	CH ₃	3.45 min	499
16	H₃C ✓	3.77 min	402				
		3.77 Hun	493	25	OCH3	3.50 min	515
17	н,с	4.31 min	521	26		3.39 min	515
	~				СН30		
18	~~	3.02 min	449	27	M	3.60 min	521
					CI		
19		4.00 min	543	28	C _{Br}	3.60 min	565
20	~	3.42 min	485	29	<u> </u>	2.05	
		3.42 11111	463	29	Ph	3.95 min	561
21	\bigcirc	3.45 min	491	30		3.79 min	521
					CI		
22		3.43 min	499	31		3.67 min	535
						·	

-46-

23	HgC	3.62 min	499	32	0~	3.56 min	513
<u> </u>				L		1	

The following compounds were synthesized as described in the above Scheme 3, (Path A) using various resin linked amides 1-11 in the place of carbamate (1-8). These compounds were characterized using LC and MS as shown in Table 3.

5 Example 33

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-(isobutyrylamino)propanoic acid.

Example 34

10 (2S)-2-(hexanoylamino)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 35

15

20

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-(pentanoylamino)propanoic acid.

Example 36

(2S)-2-[(3,3-dimethylbutanoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 37

(2S)-2-[(cyclohexylcarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

25 Example 38

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid.

Example 39

30 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid.

Example 40

(2S)-2-[(2-cyclohexylacetyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 41

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid.

-47-

Example 42

(2S)-2-[(2-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 43

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-methylbenzoyl)amino]propanoic acid.

10 Example 44

5

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid.

Example 45

15 (2S)-2-[(4-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 46

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid.

Example 47

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid.

Example 48

(2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

30 Example 49

25

(2S)-2-[(2-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 50

35 (2S)-2-[(4-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 51

(2S)-2-[(2,3-dimethylbenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 52

(2S)-2-[(3-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Table 3

Ex.	R9	LC @ 254 nm	(M+H)*	Ex.	R9	LC @ 254 nm	(M+H) ⁺
33	H ₃ C	3.03 min	436	43	СН	3.42 min	484
34	H ₃ C	3.46 min	464	44	Стосн,	3.48 min	500
35	H ₃ C	3.24 min	450	45	cr	3.70 min	504
36	+	3.37 min	464	46	HgC	3.57 min	484
37	O	3.49 min	476	47	ньсо	3.44 min	500
38		3.35 min	484	48	H ₃ C CH ₃	3.59 min	488
39	0~	3.54 min	498	49	Br	3.39 min	548
40	8	3.62 min	490	50	8	3.76 min	548
41	0~	3.66 min	496	51	СН3	3.58 min	498
42	Cci	3.36 min	504	52	Ci	3.70 min	504

Example 53 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (3-4)
(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (3-3)

5

10

The resin 1-8 (100mg) was washed with DMF to swell the resin and was treated with a solution of 2,3,4,5,6-pentafluorophenyl 2-hydroxy-4-[2-(pyrimidine-2-ylamino)ethoxy]-benzoate 2-5 (110 mg; 0.25mmole) in DMF. The reaction mixture was shaken at room temperature for 16h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resulting resin 3-3 was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

The resin 3-3 was treated with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 3-4 was purified via preparative HPLC. 3.907 min (78% @ 220 nm); MS m/z 476 (M+H)⁺.

20

30

The following compounds were synthesized as described in the above Scheme 3 (Path B), using various resin bound carbamates in the place of (1-8). These compounds were characterized using LC and MS as shown in Table 4.

Example 54

25 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(phenoxycarbonyl)amino]propanoic acid.

Example 55

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 56

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

-50-

Example 57

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyphenoxy)carbonyl]amino}propanoic acid.

5 Example 58

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

Example 59

10 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 60

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

Example 61

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(4-nitrobenzyl)oxy]carbonyl}amino)propanoic acid.

20

15

Example 62

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid.

25 Example 63

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

Example 64

30 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methylphenoxy)carbonyl]amino}propanoic acid.

Example 65

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid.

Example 66

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid.

40

35

Example 67

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.

-51-

Example 68

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

5 Example 69

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 70

10 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Table 4

Ex.	R9	LC @ 254 nm	(M+H)*	Ex.	R9	LC @ 254 nm	(M+H)*
54	Phenyl	3.77 min	481	62	n-Hexyl	4.26 min	490
55	Benzyl	3.88 min	495	63	Propargyl	3.30 min	444
56	i-Butyl	3.73 min	461	64	p-Me-Phenyl	3.94 v	496
57	p-OMe-phenyl	3.75 min	511	65	Methyl	3.06 v	420
58	Octyl	4.79 min	517	66	Ethyl	3.26 min	434
59	n-Butyl	3.77 min	462	67	n-Propyl	3.48 v	448
60.	CCI3CH2	3.94 min	538	68	i-Propyl	3.46 v	448
53	neopentyl	3.90 min	476	69	Allyl	3.40 min	446
61	p-NO2-Benzyl	3.80 min	541	70	Homoallyl	3.58 min	460

15

The following compounds were synthesized as described in the above Scheme 3 (Path B), using various resin bound ureas 1-9 in the place of (1-8). These compounds were characterized using LC and MS as shown in Table 5.

-52-

Example 71

(2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoyl}amino)propanoic acid

5 Example 72

(2S)-2-{[(tert-butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 73

10 (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 74

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy}benzoyl}amino)-2-{[(4-methoxyanilino)carbonyl]amino)propanoic acid

Example 75

(2S)-2-{[(2-ethylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

20

Example 76

(2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid

25 Example 77

(2S)-2-{[(2,4-dichloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 78

30 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid.

Example 79

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid.

Example 80

(2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

40

Example 81

(2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

-53-

Example 82

(2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 83

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid.

Example 84

10 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethyl)anilino]carbonyl}amino)propanoic acid.

Example 85

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid.

Example 86

(2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

20

15

Example 87

(2S)-2-{[(4-fluoroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

25 Example 88

(2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 89

30 (2S)-2-({[4-(ethoxycarbonyl)anilino]carbonyl}amino)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 90

(2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 91

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid.

40

35

Example 92

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

-54-

Example 93

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid

5 Example 94

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octylamino)carbonyl]amino}propanoic acid

Table 5

Ex.	R9	LC @ 254 nm	(M+H)*	Ex.	R9	LC @ 254 nm	(3.5.77)+
			(1.1.1.1)	2	R)	20 6 254 11111	(M+H)*
71	O	3.70 min	480	83	1)	3.79 min	495
72	+	3.45 min	460	84	F ₃ C	4.22 min	549
73	~~	3.50 min	460	85	F ₃ CO	4.27 min	565
74		3.56 min	510	86	ران	3.96 min	515
75	α	3.81 min	508	87	F	3.68 min	499
	~	3.13 min	444	88		3.50 min	523
77	cr	4.19 min	549	89	~	3.92 min	553
78	\	3.63 min	495	90	()	3.66 min	487
79	CV.	3.68 min	511	91	\Leftrightarrow	3.86 min	487

-55-

80	Ccı	3.78 min	515	92	0	3.55 min	495	
81	Br	3.80 min	559	93	0~	3.70 min	509	
82	CX _{Ph}	4.13 min	557	94	~~~	4.56 min	517	

Scheme 4

5 2(S)-(2,2-dimethyl-propoxycarbonylamino)-3-{[2-Hydroxy-4-(2-fluorenylmethyloxy-carbonylamino)ethoxylbenzoylamino}-propionic acid on Wang Resin (4-1)

The resin 1-8 was washed with DMF to swell the resin. A solution of 4-[(2-fluorenylmethyloxycarbonylamino)ethoxy]-2-hydroxybenzoic acid (2-6) (628.5 mg; 1.5 mmole) in DMF was mixed with diisopropylcarbodiimide (189 mg; 1.5 mmole), hydroxybenzotriazole (202.5 mg; 1.5 mmole) and dimethylaminopyridine (18.33 mg; 0.15 mmole) and the mixture was added to the resin. The reaction mixture was shaken

-56-

at room temperature for 16h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

2(S)-(2.2-dimethyl-propoxycarbonylamino)-3-[2-Hydroxy-4-(2-aminoethoxy)benzoyl-amino]-propionic acid on Wang Resin (4-2)

The resin 4-1 was shaken with a solution of 20% piperidine in DMF (5mL) for 10 min and filtered. Another 5mL portion of 20% piperidine in DMF was added and shaken at room temperature for 20 min. The resin was filtered and washed with DMF (3 x 40mL), MeOH (3 x 40mL) and DCM (3 x 40mL). The resin were dried under vacuum.

A sample of the resin was removed and subjected to cleavage with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. The product was characterized by HPLC: 3.35 min (70% @ 220 nm); MS m/z 398 (M+H)⁺.

5

10

WO 99/52879

-57-

PCT/US99/08180

Scheme 5

Example 95 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (5-2) (2S)-3-({4-[2-(4.5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (5-1)

5

10

15

The resin 4.2 (100mg; 0.1mmole) was swollen in DMF. To the resin was added a solution of 2-(3,5-dimethylpyrazolyl)-4,5-dihydroimidazole hydrobromide (123 mg; 0.5 mmole) in DMF (1.5 mL) followed by diisopropylamine (0.15 mL; 1 mmole). The reaction vessel was shaken at 60 °C for 18h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

The resin 5-1 was cleaved by treatment with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 5-2 was purified via preparative HPLC. NMR (300MHz, MeOH-d4) δ 7.7 (d, J = 7 Hz, 1H), 6.5 (m, 2H), 4.5 (q, 1H), 4.2 (t, 2H), 3.85 (m, 1H), 3.75-3.8 (m, 7H), 3.5 (t, 2H), 0.9 (s, 9H). HR-MS FAB m/z for $C_{21}H_{31}N_5O_7$ calcd. 466.2302 (M⁺+1), obsd. 466.2289.

The following compounds were synthesized as described in the above Scheme 5 (Path A), using various resin bound carbamates in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 6.

Example 96

5

15

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 97

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid.

20 Example 98

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(ethoxycarbonyl)amino]propanoic acid.

Example 99

25 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid.

Example 100

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

Example 101

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 102

35

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 103

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

5 Example 104

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(hexyloxy)carbonyl]amino}propanoic acid.

Example 105

10 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

Example 106

(2S)-2-[(butoxycarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 107

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

20

15

Table 6

Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
97	Methyl	2.82 min	410	104	n-Hexyl	3.97 min	480
98	Ethyl	2.99 min	424	105	n-Octyl	4.49 min	508
99	n-Propyl	3.21 min	438	95	(CH3)3CCH2	3.63 min	466
100	i-Propyl	3.17 min	438	106	n-Butyl	3.46 min	452
101	Allyl	3.13 min	436	107	i-Butyl	3.44 min	452
102	Homoallyl	3.31 min	450	96	Benzyl	3.60 min	486
103	Propargyl	3.01 min	434				

The following compounds were synthesized as described in the above Scheme 5 (Path A), using various resin bound ureas in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 7.

-60-

Example 108

(2S)-2-{[(butylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

5 Example 109

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(hexylamino)carbonyl]amino}propanoic acid.

Example 110

10 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid.

Example 111

(2S)-2-{[(allylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 112

(2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

20 Example 113

15

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 114

3-({4-[2-(2,5-dihydro-1H-imidazol-4-ylamino)ethoxy]-2-hydroxybenzoyl)amino-N-({{(1S,2R)-phenylcyclopropyl]amino)carbonyl alanine.

Example 115

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid.

Example 116

(2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 117

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid.

30

Table 7

Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H)*
108	н,с~	3.20 min	451	113	0	3.26 min	485
109	H ₃ C	3.69 min	479	114		3.57 min	511
110	H ₃ C	4.24 min	507	115	С осн,	3.42 min	501
111	~	2.84 min	435	116	CV _{Ph}	3.89 min	547
112	O	3.37 min	477	117	0~	3.47 min	499

The following compounds were synthesized as described in the above **Scheme 5** (Path A), using various resin bound amides in the place of **4-2**. These compounds were characterized using LC and MS as shown in **Table 8**.

Example 118

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(isobutyrylamino)propanoic acid.

Example 119

10

(2S)-2-(butyrylamino)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

- Example 120
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(hexanoylamino)propanoic acid.

Example 121

20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pentanoylamino)propanoic acid.

-62-

Example 122

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3,3-dimethylbutanoyl)amino]propanoic acid.

5 Example 123

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid.

Example 124

10 (2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 125

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pent-4-ynoylamino)propanoic acid.

Example 126

(2S)-2-[(cyclohexylcarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 127

20

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid.

25 Example 128

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid.

Example 129

30 (2S)-2-[(2-cyclohexylacetyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 130

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(E)-3-phenylprop-2-enoyl]amino)propanoic acid.

Example 131

(2S)-2-[(2-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 132

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2-methylbenzoyl)amino]propanoic acid.

Example 133

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid.

5 Example 134

(2S)-2-[(4-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 135

10 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid.

Example 136

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid.

Example 137

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid.

20

Example 138

(2S)-2-[(2-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

25 Example 139

(2S)-2-[(4-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 140

30 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,3-dimethylbenzoyl)amino]propanoic acid.

Example 141

. .

35

(2S)-2-[(3-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethoxy]-2-hydroxybenzoyl)amino)propanoic acid.

-64-

Table 8

Ex.	R9	LC @ 254 nm	(M. YE)+	F		LC @ 254 nm	(A.F. 74)+
Ex.	l RG	20 9 23 4 1111	(M+H) ⁺	Ex.	R9	LC @ 234 nm	(M+H)*
118	H ₃ C	2.90 min	422 (M+H)	130	0~	3.57 min	482 (M+H)
119	H ₃ C	2.90 min	422 (M+H)	131	(X _c	3.24 min	490 (M+H)
120	н₃с	3.34 min	450 (M+H)	132	СНа	3.30 min	470 (M+H)
121	н,с	3.10 min	436 (M+H)	133	OCH ₃	3.38 min	486 (M+H)
122	+	3.26 min	450 (M+H)	134		3.59 min	490 (M+H)
123	н,с ЩЕ н,с	3.71 min	476 (M+H)	135	H ₃ C	3.46 min	470 (M+H)
124	D-	3.90 min	528 (M+H)	136	нусо	3.34 min	486 (M+H)
125	~	2.86 min	432 (M+H)	137	н,с Сн,	3.45 min	474 (M+H)
126	\Diamond	3.36 min	462 (M+H)	138	Br	3.16 min	534 (M+H)
127	3	3.22 min	470 (M+H)	139	B	3.28 min	534 (M+H)
128	0~	3.42 min	484 (M+H)	140	СН	3.65 min	484 (M+H)
129	○	3.50 min	476 (M+H)	141	, cı	3.56 min	490 (M+H)

Example 142 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (5-4)

5

10

(2S)-3-({2-hydroxy-4-[2-(3.4.5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (5-3)

The resin 4-2 (100 mg: 0.1mmole) was swollen in dioxane and treated with a solution of 1-aza-2-methoxy-1-cycloheptene (127 mg; 1 mmole) in dioxane (1.5 mL). The reaction mixture was shaken at room temperature for 18h. The mixture was filtered and the resin was washed with dioxane (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

15

20

The resin 5-3 was cleaved by tratment with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 5-4 was purified via preparative HPLC. NMR (300MHz, DMSO-d6) δ 12.8 (s, 1H), 9.55 (t, 1H), 9.25 (t, 1H), 8.8 (t, 1H), 7.8 (d, J = 9 Hz, 1H), 7.7 (d, J = 8 Hz, 1H), 7.3 (m, 5H), 6.5 (m, 2H), 5.0 (s, 2H), 4.3 (q, 1H), 4.2 (t, 2H), 3.8 (m, 3H), 3.6 (m, 1H), 3.5 (m, 2H), 2.7 (m, 2H), 1.7 (m, 2H), 1.6 (m, 4H).

25

The following compounds were synthesized as described in the above Scheme 5 (Path B), using various resin bound carbamates in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 9.

-66-

Example 143

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 144

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid.

Example 145

10 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 146

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid.

Example 147

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

Example 148

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

25 Example 149

20

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 150

30 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

Example 151

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 152

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

Example 153

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

-67-

Example 154

(2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 155

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

10

Table 9

Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H)*
144	Methyl	3.08 min	437	151	n-Hexyl	3.19 min	507
145	Ethyl	3.25 min	451	152	n-Octyl	4.67 min	535
146	n-Propyl	3.46 min	465	142	(CH3)3CCH2	3.85 min	493
147	i-Propyl	3.38 min	465	153	(CC13)3CCH2	3.89 min	553
148	Allyi	3.37 min	463	154	n-Butyl	3.70 min	479
149	Homoallyl	3.55 min	477	155	i-Butyl	3.67 min	479
150	Propargyl	3.27 min	461	143	Benzyl	3.83 min	513

-68-

Scheme 6

Example 156 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxy-benzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (6-2)

5

10

15

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (6-1)

The resin 4-2 (100 mg; 0.1 mmole) was swollen in DMF and treated with a solution of 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (145 mg; (0.5 mmole) in DMF (1.5 mL) followed by diisopropylamine (0.15 mL; 1 mmole). The reaction mixture was shaken at room temperature for 18h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

The resin 6-1 was cleaved by tratment with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 6-2 was purified via preparative HPLC. NMR (300MHz, MeOH-d4) δ 7.7 (d, J = 7 Hz, 1H), 6.5 (m, 2H), 4.5 (q, 1H), 4.2 (m, 2H), 3.85 (m, 1H), 3.8 (m, 2H), 3.75 (m, 1H), 3.7 (m, 2H), 0.9 (s, 9H).

HR-MS FAB m/z for $C_{19}H_{29}N_5O_7$ calcd. 440.2145 (M⁺+1), obsd. 440.2154.

10

5

The following compounds were synthesized as described in the above Scheme 6 (Path A), using various resin bound carbamates in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 10.

15 Example 157

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid.

Example 158

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid.

Example 159

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid.

Example 160

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid.

Example 161

30

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid.

35 Example 162

(2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

-70-

Example 163

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid.

5 Example 164

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid.

Example 165

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

Example 166

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid.

Example 167

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

20 Example 168

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[([1,1'-biphenyl]-2-ylmethoxy)carbonyl]amino}propanoic acid.

25 Example 169

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(4-bromobenzyl)oxy]carbonyl}amino)propanoic acid.

Example 170

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(4-fluorobenzyl)oxy]carbonyl}amino)propanoic acid.

Example 171

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(2-bromobenzyl)oxy]carbonyl}amino)propanoic acid.

Example 172

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[({[4-(trifluoromethyl)benzyl]oxy}carbonyl)amino]propanoic acid.

40

Table 10

Ex.	R9	LC @ 254 nm	(M+H)+	Ex.	R9	LC @ 254 nm	(M+H)*		
158	Methyl	2.75 min	384	165	(CC13)3CCH2	3.60 min	502		
159	Ethyl	2.93 min	2.93 min 397		n-Butyl	3.39 min	426		
160	n-Propyl	3.15 min	412	157	Benzyl	3.53 min	460		
161	i-Propyl	3.11 min	412	168	(C) _{Ph}	4.20 min	536		
162	Aliyi	3.05 min	410	169	B _r	3.85 min	539		
163	Homoallyl	3.25 min	424	170	, C)	3.60 min	478		
167	Propargyl	2.95 min	408	171	Br	3.81 min	539		
166	n-Hexyl	3.91 min	4454	172	F,C	3.97 min	528		
156	(СН3)3ССН2	3.57 min	440						

The following compounds were synthesized as described in the above Scheme 6 (Path A), using various resin bound ureas in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 11.

Example 173

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-10 toluidinocarbonyl)amino]propanoic acid.

Example 174

 $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-hydroxybenzoyl]amino\}-2-hydroxybenzoyl]amino\}-2-hydroxybenzoyl]amino}-2-hydroxybenzoylamino}-2-hydroxybenzoylamino}-2-hydroxybenzoylamino}-2-hydroxybenzoylamino}-2-hydroxybenzoylamino}-2-hydrox$ {[(2-methoxyanilino)carbonyl]amino}propanoic acid.

Example 175

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-chloroanilino)carbonyl]amino}propanoic acid.

Example 176

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-bromoanilino)carbonyl]amino}propanoic acid.

Example 177

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}propanoic acid.

15 Example 178

10

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-toluidinocarbonyl)amino]propanoic acid.

Example 179

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid.

Example 180

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-chloroanilino)carbonyl]amino}propanoic acid.

Example 181

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-fluoroanilino)carbonyl]amino}propanoic acid

Example 182

30

(2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]-amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

35 Example 183

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(cyclohexylamino)carbonyl]amino}propanoic acid.

Example 184

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid.

Example 185

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzylamino)carbonyl]amino}propanoic acid.

-73-

5 Example 186

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid.

Example 187

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(octylamino)carbonyl]amino}propanoic acid.

Example 188

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid.

Example 189

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(anilinocarbonyl)amino]propanoic acid.

Table 11

Ex.	7	1.00					
<u> </u>		LC @ 254 nm	(M+H)*	Ex.	R1	LC @ 254 nm	(M+H) ⁺
187	н,с	4.18 min	481	182	H ₃ C	3.26 min	487
189	O	3.29 min	445	175	C c	3.46 min	481
183	Q	3.32 min	451	176	Br	3.48 min	525
185	0	3.20 min	459	177	CV _{Ph}	3.81 min	521
173	CH,	3.32 min	459	181	-CJ	3.39 min	463
178	н,с	3.50 min	459	180	a C	3.68 min	481
188	н,со	3.27 min	475	184		3.57 min	495
174	Стосн,	3.36 min	475	186	0	3.37 min	473
				179	CF ₃ O	3.92 min	529
The fo	llowing compo	ande men	-41		·		

The following compounds were synthesized as described in the above Scheme 6 (Path A), using various resin bound amides in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 12.

Example 190

10

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isobutyrylamino)propanoic acid.

-75-

Example 191

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(butyrylamino)propanoic acid.

Example 192

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(hexanoylamino)propanoic acid.

10 Example 193

5

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pentanoylamino)propanoic acid.

Example 194

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3,3-dimethylbutanoyl)amino]propanoic acid.

Example 195

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid.

Example 196

(2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}-ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

Example 197

25

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pent-4-ynoylamino)propanoic acid.

30 Example 198

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(cyclohexylcarbonyl)amino]propanoic acid.

Example 199

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-phenylacetyl)amino]propanoic acid.

Example 200

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-phenylpropanoyl)amino]propanoic acid.

Example 201

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-cyclohexylacetyl)amino]propanoic acid.

Example 202

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid.

_

5

Example 203

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-chlorobenzoyl)amino]propanoic acid.

10 Example 204

 $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(2-methylbenzoyl)amino]propanoic acid.$

Example 205

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxybenzoyl)amino]propanoic acid.

Example 206

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-chlorobenzoyl)amino]propanoic acid.

Example 207

 $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-[(4-methylbenzoyl)amino]propanoic acid.$

25

Example 208

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxybenzoyl)amino]propanoic acid.

30 Example 209

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(pyridin-3-ylcarbonyl)amino]propanoic acid.

Example 210

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isonicotinoylamino)propanoic acid.

Example 211

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid.

Example 212

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-bromobenzoyl)amino]propanoic acid.

Example 213

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-bromobenzoyl)amino]propanoic acid.

Example 214

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,3-dimethylbenzoyl)amino]propanoic acid.

Example 215

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-chlorobenzoyl)amino]propanoic acid.

15

Example 216

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(benzoylamino)propanoic acid.

20 Example 217

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-ethylbenzoyl)amino]propanoic acid.

Example 218

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-butoxybenzoyl)amino]propanoic acid.

Table 12

F	DO	LC @ 254 nm (M+H)+		T =	т				
Ex.	R9	LC @ 254 mm	(M+H)*	Ex.	R9	LC @ 254 nm	(M+H)*		
190	н _з с н _з с	2.88 min	396 (M+H)	205	ОСН,	3.38 min	460 (M+H)		
191	н,с	2.88 min	396 (M+H)	206	cr	3.58 min	464 (M+H)		
192	H ₃ C	3.34 min	424 (M+H)	207	н	3.45 min	444 (M+H)		
193	н,с~	3.09 min	410 (M+H)	208	нусо	3.33 min	460 (M+H)		
194	+	3.24 min	424 (M+H)	209		2.61 min	431 (M+H)		
195	н,с ЦЕ н,с	3.70 min	450 (M+H)	210		2.58 min	431 (M+H)		
196	D	3.85 min	502 (M+H)	211	H3C CH3	3.45 min	448 (M+H)		
197	>	2.84 min	406 (M+H)	212	Br	3.27 min	509 (M+H)		
198	O	3.35 min	436 (M+H)	213	в	3.65 min	509 (M+H)		
199	0	3.21 min	444 (M+H)	214	CH ₃	3.65 min	458 (M+H)		
200	0~	3.42 min	458 (M+H)	215	CI	3.46 min	464 (M+H)		
201	○	3.50 min	450 (M+H)	216	O	3.19 min	430 (M+H)		
202	0~	3.55 min	456 (M+H)	217	N.	3.66 min	458 (M+H)		

-79-

203	Cci	3.25 min	464 (M+H)	f)	п-вио	4.08 min	502 (M+H)
204	СН	3.29 min	444 (M+H)				

Example 219 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxy-benzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (6-4)

5 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (6-3)

10

15

The resin 4-2 (100 mg; 0.1mmole) was swollen in 1:1 tetrahydrofuran and dichloromethane. To it was added a solution of 4-nitrophenylchloroformate (50 mg; 0.25 mmole) in 1:1 THF: DCM (1.5 mL) followed by diisopropylamine (0.075 mL; 0.5 mmole). The reaction mixture was shaken at room temperature for 30 min. The mixture was filtered and the resin was washed with THF (4 x 4 mL) and dichloromethane (4 x 4 mL) and dried. The resin was suspended in DMF (1.5 mL) and benzyl amine (54 mg; 0.5 mmole) was added followed by triethylamine (101 mg; 1 mmole). The reaction mixture was shaken at room temperature for 2 h. The mixture were filtered and the resin in each vessel was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum.

The resin 6-3 was cleaved by treatment with dichloromethane (0.5 mL) and trifluroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 6-4 was purified via preparative HPLC. NMR (300MHz, MeOH-d4) δ 7.65 (d, J = 7 Hz, 1H), 7.25 (m, 5H), 6.5 (m, 2H), 4.4 (q, 1H), 4.3 (s, 2H), 4.15 (t, 2H), 3.85 (m, 1H), 3.75 (m, 2H), 3.5 (t, 2H). 0.9 (s, 9H).

-80-

HR-MS FAB m/z for $C_{26}H_{34}N_4O_8$ calcd. 531.2455 (M⁺+1), obsd. 531.2459.

The following compounds were synthesized as described in the above **Scheme 6** (Path B), using various amines in the place of benzyl amine. These compounds were characterized using LC and MS as shown in **Table 13**.

Example 220

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid.

10 Example 221

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid.

Example 222

15 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid.

Example 223

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid.

Example 224

20

25

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid.

Example 225

(2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[(benzylamino)carbonyl]amino}-ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

30 Example 226

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid.

Example 227

35 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

Example 228

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-40 {[(hexyloxy)carbonyl]amino}propanoic acid.

Example 229

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(octyloxy)carbonyl]amino}propanoic acid.

-81-

Example 230

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

5 Example 231

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid.

Example 232

10 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isobutoxycarbonyl)amino]propanoic acid.

Example 233

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 234

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid.

20

Example 235

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]-carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

25 Example 236

(2S)-3-({2-hydroxy-4-[1-({(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.

Example 237

30 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

Example 238

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-

35 ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 239

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid

Example 240

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

-82-

Example 241

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 242

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

Example 243

10 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid.

Example 244

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-

ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

Example 245

(2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 246

20

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

25 Example 247

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 248

30 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)-ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid.

Example 249

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 250

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.

Example 251

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

35

Example 252

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 253

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 254

10 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid.

Example 255

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 256

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

Example 257

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy}-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid.

25 Example 258

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

Example 259

30 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino}-carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

Example 260

٠.

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

Example 261

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methylbenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid. LC 4.75 min.,

40 M+H 565.

Example 262

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methoxybenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid. LC 3.75 min.,

45 M+H 581.

-84-

Example 263

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(4-chlorobenzyl)amino]-carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 4.83 min., M+H 5.86.

5 Example 264

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(4-{2-[({[4-(dimethylamino)benzyl]-amino}carbonyl)amino]ethoxy}-2-hydroxybenzoyl)amino]propanoic acid. LC 3.7 min., M+H 594.

10 Example 265

(2S)-3-[(4-{2-[({[4-(aminosulfonyl)benzyl]amino}carbonyl)amino]ethoxy}-2-hydroxybenzoyl)amino]-2-{[(benzyloxy)carbonyl]amino}propanoic acid. LC 4.08 min., M+H 630.

15 Example 266

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2-hydroxy-4-{2-[({[4-(trifluoromethoxy)-benzyl]amino}carbonyl)amino]ethoxy}benzoyl)amino]propanoic acid. LC 5.06 min., M+H 635.

20 Example 267

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 4.8 min., M+H 586.

Example 268

25 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(2-methylbenzyl)amino]-carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid. LC 4.74 min., M+H 565.

Example 269

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2-bromobenzyl)amino}-carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 4.85 min., M+H 630.

Example 270

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2,4-dichlorobenzyl)amino}-carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 5.08 min., M+H 620.

Example 271

35

40

(2S)-3-({4-[2-({[(2-aminobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid. LC 3.81 min., M+H 566.

Example 272

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-2-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid. LC 3.58 min., M+H 552.

Table 13

Ex.	221-227	248-254	234-240	I	219-220	247 &	233 &
R8				ļ	228-232	255-260	241-246
R9 ↓		N		R8 → R9 ↓			
					219-220 &		
					228-232		
methyl	475 M+H	476 M+H	476 M+H	hexyl	545 M+H	546 M+H	546 M+H
İ	3.84min	2.84min	2.84min		4.90min	3.90min	3.90min
	221	248	234		228	255	241
ethyl	489 M+H	490 M+H	490 M+H	octyl	573 M+H	574 M+H	574 M+H
ļ	4.00min	3.01min	2.99min		5.37min	4.38min	4.37min
İ	222	249	235		229	256	242
n-propyl	503 M+H	504 M+H	504 M+H	(CH3)3CCH2-	531 M+H	532 M+H	532 M+H
	4.21min	3.20min	3.19min		4.58min	3.57min	3.58min
	223	250	236		219	257	243
i-propyl	503 M+H	504 M+H	504 M+H	(CCl3)3CCH2-	593 M+H	594 M+H	594 M+H
	4.19min	3.17min	3.17min		4.62min	3.62min	3.62min
	224	251	237		230	258	244
allyl	501 M+H	502 M+H	502 M+H	n-butyl	517 M+H	518 M+H	518 M+H
.	4.14min	3.12min	3.12min		4.43min	3.43min	3.43min
e '	225	252	238		231	259	245
homo-	515 M+H	516 M+H	516 M+H	i-butyl	517 M+H	518 M+H	518 M+H
allyl	4.31min	3.28min	3.29min		4.41min	3.40min	3.40min
	226	253	239		232	260	246
propargyl	499 M+H	500 M+H	500 M+H	benzyl	551 M+H	552 M+H	552 M+H
ļ	4.06min	3.01min	3.02min		4.59min	3.52min	3.55min
	227	254	240		220	247	233

Alternatively, Schemes 7-12 demonstrate the solution phase synthesis practice of this invention with detailed synthetic procedures for representative compounds.

Scheme 7.

5

10

15

20

25

30

Example 273 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid ethyl ester (8-1)

Methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate (7-1)

Methyl 2, 4-dihydroxy benzoate (14.5g, Aldrich), 2-(N-t-butoxycarbonyl)ethanol (13.9g, Aldrich) and triphenyl phosphine (22.6g, Aldrich) were combined in 350 mL of THF and cooled in ice under N₂ atmosphere. Diethyl diazodicarboxylate (DEAD, 15g, Aldrich) was added, the ice bath removed and the reaction mixture allowed to stir at ambient temperature for 15h. The solvent was removed on a rotary evaporator and the residue chromatographed on silica gel (300g, Merck silica 60), elution with CH₂Cl₂ to give 18g of methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate, as a viscous oil. NMR (300 MHz, CDCl₃) δ 11.0 (s, 1 H), 9.5 (d, J = 8Hz, 1H), 6.4 (m, 2H), 5.0 (broad, 1H), 4.0 (t, J = 5Hz, 2H), 3.91 (s, 3H), 3.54 (m, 2H), 1.45 (s, 9H), MS (+ESI) m/z 334 (M+Na)⁺.

4-(2-Aminoethoxy)-2-hydroxybenzoic acid, hydrochloride (7-2)

Ester 7-1 (7.2g) was treated with 5eq. KOH (dissolved in minimum amount of water and equal volume of 1, 4-dioxane) at room temperature until TLC indicated complete absence of starting material (3-12h). The reaction mixture was acidified (pH = 6) with the addition of 1N HCl solution and extracted with ethyl acetate. The extract was washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated on the rotary evaporator. The crude product (5.34g) was recrystallized from ether, then dissolved in 1, 4-dioxane and treated with an excess of anhydrous HCl (4M in dioxane, Aldrich). The mixture was allowed to stand at ambient temperature for 24h. Volatile materials were removed in vacuo on the rotary evaporator to give 7-2 as a hydroscopic off-white solid. NMR (400 MHz, DMSO-d6) δ 13.6 (broad, 1H), 11.6 (broad, 1H), 8.3 (broad, 3H), 7.7 (d, J = 9 Hz, 2H), 6.53 (m, 2H), 4.23 (t, J = 5Hz, 2H), 3.2 (s, broad, 2H).

10

15

20

25

30

2-Hydroxy-4-[2-(pyrimidine-2ylamino)ethoxy]benzoic acid (7-3)

A mixture of compound 7-2 (20g), diissopropylethylamine (DIPEA, 74 mL),—trimethylsilylchloride (TMSCl, 21.6 mL) and 2-bromopyrimidine (Lancaster, 13.5g) were combined in 350 mL 1, 4-dioxane at room temperature, then brought to reflux under N₂ atmosphere. After 2 days, an additional 12 mL trimethylsilyl chloride was added, and the mixture continued at reflux for an additional 2 days (until TLC showed no stating material remained). The reaction mixture was cooled to ambient temperature, concentrated to dryness in vacuo on a rotary evaporator and the residue suspended in water. The heterogeneous mixture was refluxed briefly, allowed to cool to room temperature, the product collected on a vacuum filter and air dried to give 15.3g of 7-3, as a tan powder. NMR (400 MHz, DMSO-d₆) δ 12 (very broad, 2H) 8.3 (d, J = 5 Hz, 2H) 7.7 (d, J = 9Hz, 1H), 7.28 (t, J = 6Hz, 1H), 6.57 (t, J = 5Hz, 1H), 6.49 (m, 2H), 4.13 (t, J = 6Hz, 2H), 3.62 (q, 2H); MS (+ESI) m/z 276 (M+H)⁺; IR (KBr) v (cm⁻¹) 3275, 3000, 1660, 1625.

A mixture of compound 7-3 (5.51g), N-hydroxybenzotriazole hydrate(HOBt•H₂0, 4.6g, Aldrich), N-methyl morpholine (NMM,8.8 mL) and 1-[3-(dimethylamino)-propyl]-3-ethyl carbodimide hydrochloride (DEC, 7.6g, Aldrich) were stirred at room temperature in 60 mL DMF for ~ 0.3 h, followed by the addition of 2(S)-benzenelsulfonylamino- β -alanine ethyl ester (WO9532710, Scheme 2). The mixture was allowed to stir at room temperature for 2 days under N₂ atmosphere. Volatile materials were removed in vacuo on a rotary evaporator, and the residue dissolved in ethanol. Twenty grams of silica gel (silica 60, Merck) were added and the solvent removed. Chromatography on 300g of silica gel (ethyl acetate elution, gave 8.1g of the title compound as a pale yellow glass, which upon hardening and pulverizing produced an off-white powder. NMR (400 MHz, DMSO-d₆) δ 12.5 (s, 1H), 8.68 (t, J = 6Hz, 1H), 8.48 (d, J = 9Hz, 1H), 8.27 (d, J = 5Hz, 1H), 7.73 (m, 2H), 7.64 (d, J = 9Hz, 1H), 7.55-7.5 (m, 1H), 7.48-7.44 (m, 2H), 7.27 (t, J = 6Hz, 1H), 6.58 (t, J =

-89-

5Hz, 1H), 6.47 (dd, J = 6Hz, 3Hz, 1H), 6.42 (d, J = 2Hz, 1H), 4.1 (t, J = 6Hz, 2H), 4.05 (q, J = 7Hz, 1H), 3.79 (q, J = 7Hz), 3.62 (q, 2H), 3.54 (m, 1H), 3.34 (m, 1H overlapping with H_2O peak), 0.94 (t, J = 7Hz); MS (+ESI) m/z 530 (M + H)⁺; IR (KBr) v (cm⁻¹) 3400, 1740, 1650, 1580.

5

-90-

Example 274 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid (8-2).

To a solution of compound 8-1 (8.1g), dissolved in 75 mL 1, 4-dioxane, was added a solution of NaOH (4g) in 75 mL H_2O and the reaction mixture was stirred at room temperature for 15h. The mixture was concentrated in vacuo and the residue partitioned between water and dichloromethane. The aqueous phase was acidified with 1N aqueous HCl solution to pH 7, which produced a gum precipitate. This material (7g) was absorbed onto 15g of silica gel as in example 1, followed by chromatography on 200g silica gel. Elution with chloroform (90)-methanol (10)-acetic acid (0.1) gave the title compound as an amber syrup. MS (-ESI) m/z 500 (M-H); $[\alpha]_D^{25} = 6.84$ (c. 9.497, methanol).

Analysis for: C₂₂H₂₃N₅O₇S:

5

10

Calculated: C, 52.69; H, 4.62; N, 13.96.

15 Found: C, 52.65; H, 4.43; N, 13.6.

Example 275 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride (8-3).

A mixture of compound 8-2 (8g) and 10% Pd/C (1g) was stirred at room temperature in 1, 4-dioxane (125 mL), acetic acid (125 mL), water (50 mL) and concentrated HCl (2 mL) under H₂ atmosphere (balloon) for 2 days. Celite was added to the mixture with stirring for 0.25h, and the mixture was filtered through a pad of celite with the aid of isopropanol. The filtrate was concentrated on the rotary evaporator and the residue treated sequentially with (1)warm heptane, then concentrated; (2) 1:1 water -1, 4-dioxane, then filtered and concentrated, followed by vacuum drying in an abderhalden apparatus (isopropanol, reflux) to give the title compound 8-3 (4.7g) as a hygroscopic white powder. NMR (400 MHz, DMSO-d₆) δ 12.6 (broad, 2H) 8.77 (broad, 1H), 8.2 (broad, 1H), 8.1 (broad, 2H), 7.72 (m, 3H), 7.47-7.37 (m, 3H), 6.46 (m, 1H), 6.44 (s, broad, 1H), 4.07 (t, J = 5Hz, 2H), 3.93 (broad, 1H), 3.63 - 3.43 (m, 1H), 3.4 - 3.25

(m, 2H), 1.9 - 1.77 (m, 2H); IR (KBr) v (cm⁻¹) 3360, 1720, 1580; MS (+ESI) m/z 506 $(M+H)^+$.

Example 276 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride (8-4)

The above acid (8-3) was dissolved in ethanol (25 mL) and concentrated HCl (1 mL). The mixture was heated to reflux for 15h, concentrated on a rotary evaporator and filtered through a short plug of silica gel with the aid of ethanol to give the title compound as a hygroscopic tan powder. IR(KBr) v (cm⁻¹) 1745, 1690; MS (+ESI) m/z 534 (M+H)⁺.

Analysis for C24H31N5O7S•HCl.

Calculated: C, 50.57; H, 5.66; N, 12.29.

Found: C, 50.71; H, 5.66; N, 12.53

10

Scheme 9

$$H_2/Pd/C$$
 $HCI - AcOH$
 HCI

5

10

15

20

25

30

Example 277 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride (9-2).

2-Hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2ylamino) ethoxy]-benzoic acid (9-1).

Compound 7-3 (2g) was combined with 10% Pd/C (0.5g), acetic acid (100 mL) and concentrated hydrochloric acid (0.7 mL). The mixture was stirred at room temperature under an atmosphere of H_2 (balloon) for 2 days. Celite was added and the mixture stirred for 0.5h, then filtered through a pad of celite with the aid of isopropanol. Volatile materials were removed on the rotary evaporator and the residue warmed with heptane (~0.5h, 100°C) followed by concentration in vacuo to give 9-1 as a tan foam. NMR (400 MHz, DMSO-d₆) δ 12.9 (broad, 2H), 8.25 (s, broad, 2H), 7.85 (t, J = 6Hz, 1H), 7.66 (d, J = 9 Hz, 1H), 6.48 - 6.41 (m, 2H), 4.07 (t, J = 5Hz, 2H), 3.56 - 3.50 (m, 2H), 3.22 (m, 2H, overlapping with H_2O peak), 1.79 (m, 2H); IR (KBr) v (cm⁻¹) 3450 (broad); MS (+ESI) m/z 280 (M + H)⁺.

Compound 9-1 (1.58g), 3-amino-2(S)-benzyloxycarbonylaminopropionic acid, ethyl ester hydrochloride (1.51g; from the amino acid (Fluka) esterified with HCl in ethanol), N-methyl morpholine (NMM, 1.52gand benzotriazol-1yloxytris(dimethylamino) phosphoniumhexafluorophosphate (BOP, 2.21g) were combined in 40 mL anhydrous DMF. The mixture was stirred for 48h at room temperature, additional BOP reagent (1g) was added and the reaction stirred for 15h. Volatile materials were removed on the rotary evaporator, the residue dissolved in ethanol and absorbed onto 20g silica gel, and this added to the top of a 200g silica gel Flash chromatography, elution with chloroform-methanol-acetic acid column. (90:10:1) followed by treatment with an equivalent concentrated aqueous HCl in ethanol and concentration provided the title compound as a hygroscopic tan powder. NMR (400 MHz, DMSO-d₆) δ 12.7 (s, 1H), 8.85 (t, J = 6 Hz, 1H), 8.00 (s, broad,

WO 99/52879

2H), 7.84 (d, J = 7.5Hz, 1H), 7.80 (d, J = 9 Hz, 1H), 7.60 (t, J = 6 Hz, 1H), 7.32 (m, 5H), 6.49-6.45 (m, 2H), 5.02 (s, 2H), 4.27 (q, 1H), 4.06 (m, 4H), 3.66 - 3.55 (m, 2H), 3.49 (m, 2H), 3.23 (m, 4H), 1.79 (m, 2H), 1.10 (t, J = 7 Hz, 3H); IR (KBr) v (cm⁻¹) 3300, 1730, 1650; MS (+ESI) m/z 528 (M+H)⁺.

5

10

Example 278 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride (9-3).

The above ester 9-2 was hydrolyzed to the title compound 9-3 by refluxing (15-24h) 1N aqueous HCl solution. When TLC indicated no starting ester remained, the solution was concentrated on the rotary evaporator and the residue treated with warm isopropanol, filtered and concentrated to give 9-3 as a hygroscopic tan powder. MS (+FAB) m/z 500 $(M+H)^+$; $[\alpha]_D^{25} = -7.83$ (c. 5.36, MeOH).

Analysis for C₂₄H₂₉N₅O₇•HCl• H₂O;

Calculated: C, 52.03; H, 5.82; N, 12.64. 15

Found:

C, 52.02, H, 5.53; N, 12.00.

Scheme 10

Example 279 3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride. (10-4)

5

10

15

20

25

30

Compound 10-1 (1.33g, scheme 7) and β-phenylalanine ethyl ester hydrochloride (1.03g; from ethanol - HCl treatment of β -phenylalanine (Aldrich)) were combined in dichloromethane (20 mL) with DEC coupling agent (0.94g), HOBt (0.75g) and NMM (0.99g). The mixture was stirred at room temperature for 15h. Volatile materials were removed in vacuo on a rotary evaporator and the residue partitioned between ethyl ether and 1N aqueous HCl solution. The organic phase was washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated to give 2.8g of crude coupling product 10-2 (Scheme 10). The N-terminal Boc group was removed by dissolving the product in a minimum amount of absolute ethanol and adding an equal volume of anhydrous HCl in 1, 4-dioxane (4M, Aldrich). This mixture was allowed to stand at room temperature for 15h, concentrated in vacuo on a rotary evaporator, and treated with an excess of 5 eq. of the theoretical amount of KOH (~1.7g, ~85%, Baker) in water (20 mL) at reflux for 24h. The mixture was cooled to room temperature and acidified with 1N HCl solution to pH 6. 3,5-Dimethylpyrazol-1-carboxamidine nitrate (1g, Aldrich) and 0.75g of NaHCO3 were added and the mixture refluxed for 15h. An additional 0.2g carboxamidine were added, and reflux continued for 3h, when TLC (MeOH:CHCl3:NH4OH (2:8:0.1) indicated complete conversion of 10-3 (lower spot) to product 10-4 (upper spot). The reaction mixture was concentrated on the rotary evaporator, and the residue slurried in a mixture of MeOH-CHCl₃-NH₄OH (3:7:0.1). Anhydrous Na₂SO₄ was added and the mixture was stirred at room temperature for 12h, filtered and concentrated to give 3.4g of crude guanidino acid 10-5. This material was chromatographed on silica gel (50g), elution with MeOH-CHCl₃-NH₄OH (2:8:0.1) to give 0.65g of 10-5, contaminated with inorganic matter (inferred from C,H,N analysis). This material was treated with concentrated HCl (0.5 mL) in absolute ethanol (10 mL) at reflux for 15h, cooled to room temperature, concentrated, dissolved in EtOH (95:5), dried (MgSO₄), filtered and concentrated to give 0.34g of the title compound as a hygroscopic tan powder.

NMR (400 MHz, DMSO-d₆) δ 12.78 (s, 1H), 9.15 (d, J = 8Hz, 1H), 7.93 (d, J = 9 Hz, 1H), 7.84 (t, J = 6 Hz, 1H), 7.37 (d, J = 7 Hz, 2H), 7.32 (t, J = 7Hz, 2H), 7.25 (m, 1H), 7.1 - 7.6 (broad, 3H), 7.11 (s, broad 1H), 6.5 (dd, J = 6 Hz, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 5.48 (q, A portion of an AMX, J_{AM} = 4Hz, 1H), 4.07 (t, J = -5Hz, 2H), 4.0 (m, 2H), 3.53 (m, 2H), 3.03 (q, M portion of an AMX, J_{MX} = 16 Hz, 2H), 2.89(q, X portion of an AMX, J_{AX} = 6 Hz, 2H), 1.08 (t, J = 7 Hz, 3H); (KBr) v (cm⁻¹) 3350, 3180, 1745, 1690; MS(+FAB) m/z 415 (M+H)⁺.

Analysis for $C_{21}H_{26}N_4O_5 \bullet HCl.0 \bullet 5H_2O$

Calculated: C, 54.85; H, 6.14; N, 12.18.

10 Found: C, 54.54; H, 6.04; N, 12.58.

Example 280 3-[4-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid, hydrochloride (10-5)

15

Ester 10-4 was refluxed in 1N HCl for 15h. The reaction was cooled and concentrated in vacuo to provide the title compound as a hygroscopic tan powder.

MS (-FAB) m/z 385 (M-H)⁻; IR (KBr) ν (cm⁻¹) 3350, 3180, 1720, 1590.

Analysis for C₁₉H₂₂N₄O₅•HCl•H₂O

20 Calculated: C, 51.76; H, 5.72; N, 12.71

Found: C, 51.76; H, 5.74; N, 12.77.

-99-

Scheme 11

(J. Org. Chem. 1993, 58, 7948)

5

10

15

20

Example 281 3-[2-Hydroxy-4-[2-(pyrimidin-2ylamino)ethoxy]-benzoylamino]- 3-pyridine- 3-ylpropionic acid ethyl ester (11-2).

3-[4-(2-aminoethoxy)-2-hydroxy-benzoylamino]-3-pyridine-3-yl-propionic acid ethyl ester dihydrochloride (11-1).

Compound 10-1 (2.05g; see Scheme 1), 3-amino-3-(pyridine-3yl, propionic acid ethyl ester dihydrocloride (1.84g; see J. Org. Chem. 1993, 58, 7948), NMM (2.58g). HOBt (1.16g), and DEC (1.45g) were combined in dichloromethane (50 mL) and stirred at room temperature for 60 h. Volatile materials were removed on the rotary evaporator, the residue partitioned between ether and H₂O, the organic phase washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated to give 3.52g of crude coupled product, which was dissolved in a minimum amount of ethanol and treated with an excess of 4M HCl in anhydrous dioxane (Aldrich). After standing overnight (~15 h), volatile materials were removed on the rotary evaporator to give 3.31g of 11-1. NMR (400 MHz, DMSO-d₆) was consistent with the structure of 11-1; MS (+ FAB) m/z 374 (M + H)⁺.

Compound 11-1 (3.3lg), 2-bromopyrimidine (1.11g, Lancaster) and DIPEA (7.5 mL) were combined in dioxane (50 mL) at room temperature under N₂. Chlorotrimethylsilane (1.89 mL) was added and the mixture was brought to reflux. Stirring continued at this temperature for 4 days. The mixture was concentrated on the rotary evaporator, and the residue partitioned between aqueous HCl solution and chloroform. The aqueous phase was concentrated to a dark oil and the pH adjusted to 7 with aqueous ammonia. Volatile materials were removed in vacuo and the residue chromatographed on 200g of silica gel, elution with ethyl acetate to give 1.37g of the title compound, as an off-white powder. NMR (400 MHz, DMSO-d₆) was consistent with the structure of 11-2; (KBr) v (cm⁻¹) 1720; MS (+FAB) m/z 452 (M+H)⁺. Analysis for C₂₃H₂₅N₅O₅•O.5H₂O

30 Calculated: C, 59.99; H, 5.69; N, 15.21 Found: C, 60.45; H, 5.61; N,14.79.

5

10

15

Example 282 3-[2-Hydroxy-4-[2-(3, 4, 5, 6 - tetrahydropyrimidine-2ylamino)-ethoxy]benzoylamino]-3-pyridin-3-ylpropionic acid (5-3).

A mixture of compound 11-2 (0.9g) and KOH (0.34g) were stirred in water-dioxane mixture (1:1) at room temperature. When TLC (EtOAc) showed complete absence of starting ester, solvents were removed on the rotary evaporator, 10% Pd/C (0.2g, Aldrich) was added and the mixture suspended in acetic acid (20 mL), dioxane (10 ml), water (5 ml) and concentrated HCl (0.6 mL). The mixture was stirred at ambient temperature under H₂ atmosphere (balloon) for 2 days. Celite was added, and the mixture stirred 0.25h, filtered through a pad of celite with the aid of dioxane-water (1:1), and concentrated. The residue was chromotographed on silica gel (25g), elution with chloroform-methanol-ammonium hydroxide (7:3:0.1) to give the title compound 11-3 as an off-white hygroscopic powder. NMR (400 MHz, DMSO-d₆ + D₂O) was consistent with the structure 11-3; IR (KBr) v (cm⁻¹) 3400, 1650 (broad), 1580; MS (+FAB) m/z 428 (M+H)⁺.

Example 283 3-[2-Hydroxy-4-[2-(3, 4, 5, 6 -tetrahydropyrimidin - 2-ylamino)ethoxy] benzoylamino]-3-pyridin-3-ylpropionic acid ethyl ester dihydrochloride (11-4).

A sample of the above zwitterion 11-3 (0.285g) was esterified with absolute ethanol-HCl mixture at reflux. Concentration on the rotary evaporator gave the title compound 11-4. NMR (400 MHz, DMSO-d₆) δ 12.55 (s, broad, 1H), 9.5 (d, J = 8Hz, 1H), 8.94 (d, J = 2Hz, 1H), 8.73 (m, 1H), 8.48 (d, J = 2 Hz, 1H), 8.73 (m, 1H), 8.48 (d, J = 8 Hz, 1H), 8.1 (s, broad, 2H), 7.99 (d, J = 9 Hz, 1H), 7.86 (m, 1H), 7.68 (t, J = 6Hz, 1H), 6.5 (d, J = 2 Hz, 1H), 6.47 (m, 1H), 5.58 (q, A portion of an AMX, J_{AM} = 14 Hz, 1H), 4.08 - 4.0 (overlapping m, 4H), 3.5 (m, 2H), 3.25 - 3.19 (overlapping m, 3H), 3.09 (q, X portion of an AMX, J_{MX} = 16 Hz, J_{AX} = 6 Hz, 1H), 1.79 (m, 2H), 1.08(t, J = 7 Hz, 3H).

Analysis for $C_{23}H_{29}N_5O_5 \circ 2HCl.0 \circ 7H_2O$.

30 Calculated: C, 51.39; H, 6.00; N, 13.03.

Found: C, 51.40; H, 6.01; N, 12.56.

Scheme 12

a) KOH, 2O, then 2O; 10H15(CH2nO(CO)OtH4NO, 3CN, then HR-MS FAB m/z for C26H34N4O8 calcd. 531.2455 (M+1), obsd. 531.2459.

Example 284 2(S)-2-tert-Butoxycarbonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoylamino}propionic acid, (12-4) acetic acid salt.

5

10

Compound 12-1 (2.43g, scheme 12; obtained as for compound 8-1, Scheme 8, by substituting 2(S)-2-benzyloxycarbonylamino-3-amino propionic acid ethyl ester (from esterification of the acid (Fluka) using EtOH-HC1) for 2(S)-2-phenylsulfonylamino-3-amino propionic acid) and NaOH (4g) in 1,4-dioxane-water (~1:1) were refluxed for 1.5h. The mixture was cooled and volatile materials removed on the rotary evaporator. The residue was neutralized with aqueous 1N HCl and stirred overnight at room temperature. The precipitate was collected by vacuum filtration, re-esterified (EtOH-HCl, reflux), and chromatographed on silica gel, elution with CHCl₃./MeOH/HOAc (90:10:1→80:20:2) to give 850 mg of 12-2, as a tan powder.

15

20

25

30

The ester 12-2 (0.5g) was hydrolyzed with excess KOH in dioxane- H_2O at room temperature. When TLC analysis indicated an absence of starting material, an excess of di-tert-butyl dicarbonate was added and the mixture stirred at room temperature until complete by TLC. The mixture was concentrated on the rotary evaporator and the residue chromatographed on silica gel, elution with CHCl₃/MeOH/NH₄OH (90:1:1 \rightarrow 80:20:2) to give 200 mg of 12-3. This material was dissolved in a minimum amount of acetic acid, then diluted with an ~ volume of dioxane- H_2O (2:1). Hydrogenation (5% Pd/C (catalytic), H2, balloon, rt,) was complete within 2 days. The catalyst was filtered, and the filtrate concentrated on the rotary evaporator. The residue was stirred/concentrated sequentially with heptane and isopropanol, dissolved in CHCl₃ and treated with a mixture of activated charcoal and celite, filtered and concentrated to give the title compound 12-4 (0.18g) as a fine buff powder. NMR (400 MHz, DMSO-d₆) δ 8.85 (broad, 1H), 8.6 (broad, 1H), 8.4 (broad, 1H), 7.68 (d, J = 8.8 Hz, 1H), 6.47(overlapping peaks, 2H), 6.4 (d, J = 8.8Hz, 1H) 4.02 (t, broad, 2H), 3.88 (m, 1H), 3.45 (m, overlapping, 4H), 3.23 (m, broad, 4H), 1.9 (s, 3H), 1.8

-104-

(m, broad, 2H), 1.35 (s, 9H); IR (KBr) v (cm⁻¹) 3400 (broad), 1710, 1640; MS (ESI-) m/z 464 (M-1)+. Analysis for $C_{21}H_{31}N_5O_7$ •HOAc• H_2O

Calculated: C, 50.82; H, 6.86; N, 12.88

Found: C, 50.96; H, 6.56; N, 12.11

HPLC analysis of purity: 96.8%

In like manner, examples 284-315 (Table 14) were prepared, using the synthetic methods outlined above, as indicated by scheme numbers in the table. All final products were characterized as in Examples 1-283, and had spectra consistent with the assigned structures.

10

Am = Amidino	Pyr = pyrimidin-2-yl	Thp = tetrahydropyrimidine	$Pl_1 = phenyl$	Py = 3-pyridin-3-v
OH O R ³ O	Table 14 Europe 2015	1 able 14. Examples 284-313	R2 B4	20, 50, 50, 50

	÷	od Description	brown			yenow powder	yenow powder	WILLO WAY	ian powder	gold powder	buff powder	buff powder	buff powder	lan nowder	off-white nowder	white actuals	wille powdel	crystalline white powder	yellow powder	Copor Lot and Library
	Synth	Method	01	01	: =	; ∝	o	•	0 0	×	∞	80	∞	· 00) oc) ox	•	0 0	0	œ
-yi yrimidine yl arbonył		R ⁵	西	Ħ		: 1	.	វ 🛪	: £	ជ	Ħ	西	H	ជ	i I	: \$	2 1	= =	=	冱
Thp = tetrahydropyrimidine Thp = tetrahydropyrimidine Ph = phenyl Py = 3-pyridin-3-yl Cbz = benzyloxycarbonyl		ጁ	Ŧ	H	Η	Ξ	: II	; =	: =	-	I	Н	Ξ	Η	, HZ	NHCh2	NHCh,	ZOULI Ja OSHN	111202111	NHCbz
(R)		Ŗ.	Py	Py	Py	, 4 <u>q</u>	. Id	Ph	: á	Ξ	Ph	Ph	Ph	Ph	Ξ	I		; I	: ;	I
<u>x</u>		\mathbb{R}^2	Н	H	H	Ξ	H	Ξ	: =	11	I	H	H	Н	H	H	I	: Ξ	: :	I
Σ-χ 		~	H	H	H	I	Ξ	I	Ξ	: :	H	Н	H	н	Ξ	H	Ξ	Σ Σ	:	I
,		=	-	-	-	-	1	-	-		-	-		-	-	-		÷	-	-
!84-315 G ⁻		Ö	Am	Am	Pyr	Pyr	Pyr	Pyr	Pvr	Ē	du I	Thp	Thp	Thp	Thp	Pyr	Pyr	Pyr	. 6	гуг
Table 14. Examples 284-315		#	4	4	4	4	4	S	2	-	4 ·	4	S	2	4	4	4	4	7	t
Table 14.	Example	No.	284	285	286	287	288	289	290	201	167	767	293	293	295	296	297	298	299	111

			_						-106	5 -	_								
buff powder	fused golden powder	fine tan powder	fine off-white powder	fused tan solid	fine buff powder	fine white powder	fused tan solid	white powder	off-white powder	fine white powder	fine off-white powder	tan wax	·		fine tan powder		fin tan powder	tan powder	
12	œ	∞	∞	œ	∞	œ	∞	œ	∞	œ	8	ŏ			12		12	_p 8	
Ξ	ជ	Ξ	Н	ជ	H	H	ជ	H	西	i-Pr	t-Bu	(CH ₁),O	(CH ₁),NH-	вос	н		Ξ	H,N-C	(CH ₂ OH) _{3 ;}
H	H	Ξ	NHSO ₂ Ph	NHSO ₂ Ph	NHSO ₂ Ph	NHSO ₂ Ph	NHSO ₂ Ph	NHSO ₂ Ph	Н	NHSO ₂ Ph	NHSO ₂ Ph	NHSO ₂ Ph			NHCO ₂ -	CH2CH2C10H13	NHCO ₂ C ₁₀ H ₁₅	NHSO ₂ Ph	
Ph	Ph	Ph	I	Ξ	H	H	Н	H	Ph	H	H	Н			Ξ		I	Ξ	
Ξ	Ξ	I	H	H	Ξ.	Ξ	H	Ξ	H	Н	H	H			H		Ξ	Ξ	
Ξ	Ξ	H	H	H	H	Н	Η	Ξ	H	H	I	Η			Ξ		=	Ξ	
3	3	3	4	4	4	3	3	3	3	7	7	2			2		2	2	
Thp	Pyr	Pýr	Pyr	Thp	Thp	Pyr	Thp	Thp	Thp	Thp	Thp	Тћр			Thp		Thp	Thp	
5	2	5	2	S	Ŋ	4	4	4	2	4	4	4			4		4	4	
300	301	302	303	304	305	306	307	308	309	310	311	312			313		314	315	

Table 14 (Continued)

Vitronectin Receptor α_Vβ₃ Binding Assay

The purpose of this assay is to measure the effect of various compounds on the $\alpha_V\beta_3$ - ligand interaction.

Reagents

Plasma Membrane Isolation: 15 confluent T₁₅₀ flasks of 512P5 cells ($\alpha_{\nu}\beta_{3}$ - overexpressing cell line) are washed 2X with Dulbecco's phosphate buffered saline (D-PBS) without calcium or magnesium, pH 7.1. Cells are harvested with 10 mL of trypsin/EDTA and collected by centrifugation. The cell pellet is washed 2X with 0.5 mg/mL of soybean trypsin inhibitor, and resuspended at 10% weight/volume in homogenization buffer (25 mM Tris-HCl, pH=7.4; 250 mM sucrose). The cell suspension is homogenized with 2x30 seconds bursts of a Polytron homogenizer. The homogenate is centrifuged at 3000g for 10 minutes at 4 C. The supernatant is collected, measured, and made 100 mM in NaCl and 0.2 mM in MgSO4. The supernatant is centrifuged at 22,000g for 20 minutes at 4 C, the pellet is resuspended in 7 mL of membrane buffer (25 mM Tris-HCl, pH=7.4; 100 mM NaCl; 2 mM MgCl₂) by 5 strokes of a Dounce homogenizer (tight pestle) and recentrifuged at 22,000g for 20 minutes at 4 C. The pellet is resuspended in 0.5 mL/flask of membrane buffer (stock membranes) and frozen at -80C. Prior to use, stock membranes are Dounce homogenized and diluted 2 μL to 1000 μL in membrane buffer.

25

5

10

15

20

Compound Dilution: The stock compounds are dissolved in an appropriate vehicle (typically DMSO) and subsequently diluted in assay buffer composed as follows: 25 mM Tris-HCl (pH=7.4), 100 mM NaCl, 2 mM MgCl₂, 0.1% BSA.

Plate Preparation

30

Wells of Multiscreen-FB assay plates (Millipore MAFB NOB 50) are blocked with 150 mL of 0.1% polyethylenimine for 2 hours at

-108-

40 C. Following incubation the wells are aspirated and washed with isotonic saline solution.

Binding Assay

5

125 μ L of assay buffer is added to each well. Next, 25 μ L of labeled ligand is added to each well. 25 μ L of unlabeled ligand is added to non-specific binding wells (NSB). 25 μ L of assay buffer is added to all other wells. 2 μ L of compound is added to appropriate sample wells, and 2 μ L of DMSO is added to NSB and total binding (TB) wells. Finally, 25 μ L of membrane is added to each well.

10

The plates are covered and incubated at 37° C for 2 hours in a humidified incubator. Wells are aspirated on a Millipore vacuum manifold, and the wells are washed with 150 μ L isotonic saline solution. Wells are again aspirated. The plates are then dried for 1 hour in an 80° C vacuum drying oven. Plates are placed on a Millipore filter punch apparatus, and filters are placed in 12×75 mm polypropylene culture tubes. The samples are counted on a Packard gamma counter.

Example

20

15

Using ¹²⁵I- Echistatin (specific activity = 2000 Ci/mmol) supplied by Amersham at a final concentration of 50pM, the following parameters are routinely observed:

Input

80000 cpm

Total Counts

8000 cpm

Non-specific binding

200 cpm

25

Analysis of Results:

The individual well activity is expressed as a percentage of the specific binding; % Max, and reported as the mean ± standard deviation. Dose-inhibition relationships are generated for dose (X-axis) vs. % Max (Y-axis) for active compounds using a non-linear regression

-109-

computer program (PS-NONLIN), and IC50 values with corresponding 95% confidence intervals are estimated from 50% of maximal attachment.

Results are shown in Table 15 (VnR).

5 Reference Compounds:

10

Various Arginine-Glycine-Aspartic Acid (RGD)-containing peptides were assessed for the ability to inhibit a_vb_3 binding and the corresponding IC50 values with 95% confidence intervals were generated; peptide structures are given by the standard single letter designation for amino acids. Values obtained compared favorably with adhesion assay results.

Peptid $IC_{50} (\mu M)$ 95% Confidence Interval **GPenGRGDSPCA** 0.064 0.038 to 0.102 15 **GRGDSP** 1.493 1.058 to 2.025 GRGDTP 0.490 0.432 to 0.556 **GRGDS** 0.751 0.690 to 0.817 RGDS 1.840 1.465 to 2.262 **GRGDNP** 0.237 0.144 to 0.353 20 GdRGDSP 0.692 0.507 to 0.942 GRGESP inactive at 100 µM

References

1. Nesbitt, S. A. And M. A. Horton, (1992), A nonradioactive biochemical characterization of membrane proteins using enhanced chemiluminescence, *Anal. Biochem.*, 206 (2), 267-72.

Osteopontin- $\alpha_V \beta_3$ Cell Attachment Assay

The purpose of this assay is to measure the effect of various compounds on the RGD-dependent attachment of cells to osteopontin mediated by the $\alpha_{\nu}\beta_{3}$ integrin.

30

-110-

Reagents

Cell Suspension Media: The cells are suspended for assay in the tissue culture media used for normal culture maintenance buffered with 25 mM HEPES (pH 7.4) without serum supplementation.

5

Compound Dilution Media: The stock compounds are dissolved in an appropriate vehicle (typically DMSO) and subsequently diluted in the tissue culture media used for normal culture maintenance buffered with 25 mM HEPES (pH 7.4) supplemented with 0.2% BSA (no serum); final vehicle concentration is $\leq 0.5\%$.

10 Plate Preparation

Human recombinant osteopontin (prepared such as described in Stubbs, J. III, Connective Tissue Research, 1996, 35 (1-4), 393-399 is diluted to an appropriate concentration in Dulbecco's phosphate buffered saline (D-PBS) without calcium or magnesium, pH 7.1. 100 mL of this solution is incubated in the wells of PRO-BIND assay plates (Falcon 3915) for 2 hours at 37° C. Following incubation the wells are aspirated and washed once with D-PBS; plates can either be used immediately or stored for up to 1 week at 4° C. Prior to assay, the wells are blocked with 1% bovine serum albumin (BSA) in cell suspension media for 1 hour at 37° C. Following the blocking period, wells are aspirated and washed once with D-PBS.

20

15

Cell Suspension

25

 $\alpha V\beta 3$ -expressing cell lines are maintained by standard tissue culture techniques. For assay, the cell monolayer is washed three times with D-PBS, and the cells are harvested with 0.05% trypsin/0.53 mM EDTA (GIBCO). The cells are pelleted by low-speed centrifugation and washed three times with 0.5 mg/mL trypsin inhibitor in D-PBS (Sigma). The final cell pellet is resuspended in cell suspension media at a concentration of 10^6 cells/mL.

Attachment Assay

Incubation: 100 mL of diluted test compound is added to osteopontin-coated wells (in triplicate) followed by 100 mL of cell_suspension; background cell attachment is determined in uncoated wells. The plate is incubated at 25° C in a humidified air atmosphere for 1.5 hours. Following the incubation period, the wells are gently aspirated and washed once with D-PBS.

Cell Number Detection: The number of cells attached is determined by an MTT dye conversion assay (Promega) according to the manufacturer's instructions. Briefly, MTT dye is diluted in cell suspension media (15:85) and 100 mL is added to each well. The assay plates are incubated for 4 hours at 37° C in a humidified 5% CO₂/95% atmosphere, followed by the addition of 100 mL stopping/solubilization solution. The assay plates are covered and incubated at 370 C in a humidified air atmosphere overnight. After the solubilization period, the optical density of the wells is measured at a test wavelength of 570 nM with a reference measurement taken simultaneously at 630 nM.

Analysis of Results:

20

25

5

10

15

The individual well optical density is expressed as a percentage of the maximal attachment (% Max) wells minus background attachment, and reported as the mean ± standard deviation. Dose-inhibition relationships are generated for dose (X-axis) vs. % Max (Y-axis) for active compounds using a non-linear regression computer program (PS-NONLIN), and IC50 values with corresponding 95% confidence intervals are estimated from 50% of maximal attachment. Results are shown in Table 16 ("cell").

Reference Compounds:

30

Various Arginine-Glycine-Aspartic Acid (RGD)-containing peptides, and monoclonal antibodies (Chemicon, Temecula, CA) were assessed for the ability to inhibit osteopontin-aVb3 attachment and the corresponding IC50 values with 95% confidence intervals were generated in the SK-MEL-24 human malignant melanoma cell line;

-112-

peptide structures are given by the standard single letter designation for amino acids:

5	Peptide	IC50 (95% Confidence	ce Interval)
10	G <u>PenGRGDSPC</u> A n-Me-GRGDSP GRGDSP GRGDTP	0.58 mM (0.51 TO 0.4.0 mM (3.4 TO 4.7) 4.1 mM (3.4 TO 4.9) 5.2 mM (3.4 TO 4.9)	67)
	Antibody	Dilution	% Maximal Attachment
15	α _ν β ₅ (P1F6)	1:1000 1:100 1:10	(mean ± SD) 111 ± 3.3 112 ± 2.6 111 ± 3.3
	$\alpha_{\rm V}\beta_{\rm 3}$ (LM609)	1:1000 1:100	0 5.1 ± 1.7

20 <u>Literature References:</u>

Ruoslahti, R. Fibronectin and its receptors. Ann. Rev. Biochem. 57:375-413, 1988.

Hynes, R.O. Integrins: Versatility, modulation, and signaling in cell adhesion. *Cell*. 69: 11-25, 1992.

Osteoclast Pitting Assay

The assay is conducted as described in Murrills and Dempster (1990). Briefly,-4 x 4 x 0.2mm slices of devitalized bovine cortical bone are numbered, placed in the wells of 96-well culture plates and wetted with 100ul of Medium 199 containing Hanks salts, 10mM HEPES, pH 7.0 (Medium 199/Hanks). Bone cell suspensions containing osteoclasts are prepared by mincing the long bones of neonatal rats (Sprague-Dawley, 4-6 days old) in Medium 199/Hanks. 100uL of the suspension is then plated onto each slice and incubated 30 minutes to allow osteoclasts to adhere. The slices are rinsed to remove non-adherent cells and incubated 24h in Medium 199 containing Earle's salts, 10mM HEPES and 0.7g/L NaHCO3, which equilibrates at pH 6.9 in a 5% CO2 atmosphere. At this pH the adherent osteoclasts excavate an adequate number of resorption pits for assay purposes. Slices are fixed in 2.5% glutaraldehyde and osteoclasts counted following tartrate-resistant acid phosphatase staining. In experiments in which osteoclast numbers are significantly reduced in a particular treatment, a check is made for non-specific cytotoxicity by counting the number of contaminant fibroblast-like cells following toluidine staining. All cells are stripped from the slice by sonication on 0.25M NH4OH and the resorption pits formed by the osteoclasts during the experiment stained with toluidine blue. Resorption pits are quantified by manually counting.

Statistics

10

15

20

25

30

The experiments are conducted according to a block design with osteoclasts from each animal exposed to each treatment. Three replicate slices are used per treatment per animal, such that a total of 96 slices are examined for an experiment involving four animals and eight treatments (including control). Several parameters are recorded on a "per slice" basis: number of pits, number of osteoclasts, number of pits per osteoclast, number of fibroblast-like bone cells. SAS or JMP statistical software is used for statistical analysis. If analysis of variance reveals significant effects in the

experiment, those treatments differing significantly from control are identified using Dunnett's test. IC50s are calculated for active compounds using dose-response curves. Results are shown in Table 16 ("Bone Pitting").

Reference Compound: Rat calcitonin.

5 Clinical Relevance:

10

15

20

25

30

Osteoclasts are responsible for the bone loss that occurs in the onset of osteoporosis and anti-resorptive drugs directed against the osteoclast are a requirement for patients losing bone. Calcitonin and bisphosphonates, both used as anti-resorptives in the clinic, show significant osteoclast inhibitory activity in this assay. Hence it is a reasonable assay in which to identify novel anti-resorptives.

Reference: Murrills and Dempster (1990) Bone 11:333-344.

Effects of test compounds on PTH-induced hypercalcemia of thyroparathyroidectomized male rats.

Male thyro-parathyroidectomized (TPTX) rats (Charles River) were randomly assigned to groups of 7 rats/group. Following a baseline serum calcium determination an Alzet 1003D minipump (Alza Corporation, Palo Alto, CA) loaded with 0.3 mg/ml PTH (Bachem, Philadelphia, PA) was implanted subcutaneously in each rat. For evaluation of prophylactic effects of a test drug, another minipump with appropriate concentration of the test drug solution was implanted subcutaneously at a site away from PTH minipump. Alternatively, test drugs were administered by oral gavage as a solution or uniform suspension in an appropriate medium depending on the physical properties of the test compound. A group of 7 unimplanted TPTX rats was set aside as a normal control group. Twenty hours after minipump implantation blood was collected from each rat to confirm the presence of hypercalcemia (judged by elevation of serum calcium levels, 2 SD > normal non-implanted level). At various intervals between 0.5 and 24 hours after dosing (usually one to three time points), blood was collected from each rat and the serum evaluated for total calcium. Serum calcium levels were measured using the Nova 7 + 7 calcium auto analyzer spectrophotometrically using the Sigma test kit (#587A). Test results were

determined by the difference in serum calcium between vehicle and treatment group following PTH administration, using a one-way analysis of variance with Dunnett's test or other multiple comparison methods. Results are shown in Table 17.

5 References:

- Takeuchi M, Sakamoto S, Kawamuki K, Kudo M, Abe T, Fujita S, Murase K, and Isomura Y, (1990). Synthesis and structure activity relationship of new bisphosphonate derivative. Abstract #53, 199th American Chemical Society Meeting, Boston, MA.
- Fisher J, Caulfield M, Sato M, Quartuccio H, Gould R, Garsky V, Rodan G. Rosenblatt M, (1993). Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD) -containing protein.
 Endocrinology, Vol. 132 (3) 1411-1413.

Table 15
Representative Biological Data

Example	VnR (IC ₅₀ µM)	Example	VnR(IC ₅₀ µM)
1	0.0241	137	>1uM
2	0.187	138	0.361
3	0.123	139	>1uM
4	0.095	140	0.0978
5	0.061	141	>1 uM
6	0.108	142	1.6
7	0.092	143	4.79
8	>luM	144	
9	0.11	145	
10	0.061	149	
11	0.0696	150	
12	0.0661	151	
13	0.1828	152	
14	0.0445	153	2.4

-116-

Example	VnR (IC ₅₀ µM)	Example	VnR(IC ₅₀ μM)
15		154	
16		155	
17		156	0.25
18		157	
19		158	4.6
20	1.437	159	2
21	1.516	160	0.97
22		161	0.9
. 23	1.0216	162	1.1
24	1.48	163	1.1
25	0.6743	164	0.61
26		165	0.39
27	0.3308	166	0.8
28	0.159	167	2.6
29	0.405	168	2.0
30	1.27	169	
31	0.261	170	
32		171	
33		172	· · · · · · · · · · · · · · · · · · ·
34		173	4.28
35		174	3.89
36		175	3.8
37		176	
38		177	2.14
39		177	4.87
40		178	3.13
41			>luM
42		180	19.46
43		181	19.72
43	*	182	40.88
		183	4.98
45		184	17.88
46		185	4.57
47		186	6.99

-117-

Example	VnR (IC50µM)	Example	VnR(IC ₅₀ µM)
48		187	19.46
49		188	12.14
50		189	
51		190	6.87
52		191	>luM
53	34	192	>luM
54	34		>luM
55	100.6	193	>luM
56	85.8	194	>luM
57	03.0	195	>luM
58		196	5.7127
59	100	197	>IuM
	100	198	>luM
60		199	14.694
61		200	>luM
62	100	201	13.215
63		202	>luM
64		203	14.136
65	100	204	7.4788
66	100	205	>luM
67	100	206	>luM
68	100	207	>luM
69	100	208	
70	100	209	>1uM
71	>1uM		>luM
72	>luM	210	>luM
73	>luM	211	>luM
74		212	13.066
75	>1 uM	213	>luM
		214	2.3125
76		215	>luM
77		216	
78	>1uM	217	
79	>luM	218	
80	>luM	219	1.8

-118-

Example	VnR (IC ₅₀ μM)	Example	VnR(IC ₅₀ µM)
81	>luM	220	8.8
82	>luM	221	22.8
83	>luM	222	20.8
84		223	5.5
85	>luM	224	4.1
86	>luM	225	·5
87	>luM	226	5.2
88	>luM	227	5.1
89		228	10.2
90	>luM	229	17.1
91	>luM	230	4
92	>luM	231	6.7
93	>luM	232	3.7
94	>1 uM	233	3.3
95	0.105	234	8.7
96	0.119	235	3
97	0.77	236	1.9
98	0.15	237	2.7
99	0.088	238	
100	0.079	239	2.1
101	0.094	240	
102	0.069	241	4.1
103	0.21	242	7.9
104	0.086	243	0.69
105	0.135	244	1.6
106	0.114	. 245	· · · · · · · · · · · · · · · · · · ·
107	0.13	246	1.6
108	1.105	247	5.5
109	0.251	248	······································
110	0.544	249	
111	0.856	250	
112	1.092	251	
113	3.026	252	

Example	VnR (IC ₅₀ μM)	Example	VnR(IC ₅₀ μM)
114	3.139	253	
. 115	0.258	254	
116	2.761	255	5.31
117	1.518	256	9.08
118	>luM	257	1.26
119	>luM	258	4.31
120	>1uM	259	
121	>1uM	260	
122	>1uM	261	20.18
123	>luM	262	12.64
124	0.734	263	29.03
125	>luM	264	59.27
126	>luM	265	12.88
127	0.9546	266	29.57
128	>luM	267	10.16
129	0.6349	268	33.44
130	>luM	269	21.23
131	0.4055	270	21.66
132	0.9625	271	13.7
133	>luM	272	10.63
134	>luM	273	
135	>luM	274	
136	>luM	275	
		276	
		277	
		278	
		279	0.013
		280	12.3
		281	inactive
· · · · · · · · · · · · · · · · · · ·		282	-42%@100
		283	123
		284	inactive
· · · · · · · · · · · · · · · · · · ·		285	5

Example	VnR (IC ₅₀ µM)	Exampl	VnR(IC ₅₀ µM)
		286	2.8
		287	0.26
		288	0.003
			bone pitting IC50=0.44 μM
		289	inactive
		290	0.334
		291	0.44
		292	0.115
		293	0.006
		294	0.0035
		295	0.0018

Table 16. In Vitro Biological Data

Example	IC ₅₀	(μM)
No.	Cell A	Bone Pitting B
•		
280	78	inactive @200
297	50	25
277	0.05	0.4
278	0.02	0.5
274	18	0.9
293	48	
276	0.12	0.15
291	28	
275	0.002	0.43
299	inactive @ 100	1.9
298		
- 285	56	
286	86	
282	33	
289	34	

A Osteopontin - $\alpha \beta_3$ Cell Attachment Assay B Osteoclast Pitting Assay

Table 17. In Vivo Biological Data

Example No.	TPTX (% inhibition)	dose (mg/kg, route)
292	111*	100. s.c.
279	59	100. s.c
273	57	100. s.c.
277	86*	100. s.c.
	79*	100, p.o.
276	170*	100. s.c.
274	54*	100. s.c.
275	112*	100. s.c.
	(64)	30, s.c.
	105*	75. s.c.
	39	100, p.o.
291	41	100. s.c.
299	102*	100, p.o.

* p< 0.05 when compared to vehicle control

5

10

15

20

The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include, but are not limited to, salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and salts with organic acids such as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium. The compounds of the present invention can also be used in the form of esters at the C-terminus; carbamates, amides and the like at the N-terminus or other conventional "pro-drug" forms which, when administered, convert to the active moiety in vivo.

Compounds of the present invention may be administered in combination with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene

-122-

glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils. Adjuvents customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA. These compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. When administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions, formulations may contain, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, or elixirs containing, for example, from about 20 to 50% ethanol, and the like. When administration is parenterally, formulation may be, for example, sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% by weight of active ingredient in combination with a carrier, and more preferably between about 5% and 60% by weight of active ingredient.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

20

25

30

5

10

15

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release release form. Preferably, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response as would be

-123-

appreciated by one skilled in the art. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

-124-

CLAIMS

What is claimed is:

1. Compounds of the formula

$$G^{-}$$
 N
 R^{1}
 R^{2}
 R^{4}
 R^{5}

5 wherein:

G is

10

15

R¹ and R² are independently, hydrogen, alkyl of 1 to 6 carbon atoms, mono or bicyclic aralkyl of 6 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

R³ is hydrogen, mono or bicyclic aryl of 6 to 10 carbon atoms, 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O;

20 R⁴ is hydrogen, NHR⁹, OR⁹, NHCO₂R⁹, NHCONHR⁹, NHCOR⁹ or NHSO₂R⁹; provided that R³ and R⁴ are not both hydrogen;

10

15

30

R⁵ is hydrogen, or alkyl of 1 to 6 carbon atoms, optionally substituted with a terminal group forming a prodrug;

R⁶ and R⁷ are independently hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or aralkoxy of 6 to 10 carbon atoms;

R⁸ and R⁹ are independently hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbons, alkynyl of 2 to 10 carbons, mono or polycycloalkyl of 3-12 carbon atoms, mono or polycycloalkyl-alkyl of 4-12 carbon atoms, mono or bicyclic aryl of 6 to 10 carbon atoms, 6 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O, mono or bicyclic aralkyl of 7 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

n is an integer from 1 to 4; and m is 0 or 1; or a pharmaceutically acceptable salt thereof.

- Compounds of Claim 1 wherein G is 6-aminopyridin-2yl, pyridin-2yl,
 pyrimidin-2yl, tetrahydropyrimidin-2yl, tetrahydropyrimid-4-one-2yl, imidazol-2yl, 5-amino 1,2,4-triazol-4-yl, dihydroimidazol-2yl, amino(imino), pyridyl-urea or benzyl-urea.
 - 3. Compounds of Claim 2 wherein G is pyridin-2yl, imidzazolyl-2yl, 5-amino 1,2,4-triazol-4-yl, or tetrahydropyrimidinyl.
- 25 4. Compounds of Claim 1 wherein R_1 and R_2 are hydrogen.
 - 5. Compounds of Claim 1 wherein R₃ is hydrogen, phenyl, or pyridyl.
 - 6. Compounds of Claim 1 wherein R₄ is hydrogen or HNSO₂phenyl, HNSO₂alkyl or NHCO₂benzyl or NHCO₂neopentyl, NHCO₂adamantyl, NHCO₂CH₂adamantyl, NHCONHphenyl, NHCONHbenzyl, NHCONHalkyl, NHCOphenyl, NHCObenzyl, NHCOalkyl, NHCOadamantyl.

- 7. Compounds of Claim 1 wherein G is pyridin-2yl, 6-aminopyridin-2yl, 5-amino 1,2,4-triazol-4-yl or imidazol-2yl or dihydroimidazol-2yl or tetrahydropyrimidin-2yl, R₁, R₂ and R₃ are hydrogen, R₄ is NHSO₂phenyl, NHCO₂benzyl, NHCO₂neopentyl and R₅ is hydrogen or alkyl of 1 to 3 carbon atoms.
- 5 8. Compounds of Claim 1 wherein G is pyridin-2yl, 6-aminopyridin-2yl 5-amino 1,2,4-triazol-4yl, imidazol-2yl, dihydroimidazol-2yl, or tetrahydropyrimidin-2yl, R₁, R₂ and R₄ are hydrogen, R₃ is phenyl or pyridyl and R₅ is hydrogen or alkyl of 1 to 4 carbon atoms.
 - 9. Compounds of Claim 1 wherein n is 2 or 3.
- 10. A compound of Claim 1 where G is 1,4,5,6-tetrahydropyrimidyl and R_4 is NHCO₂ R_9 .
 - 11. A compound of Claim 1, which is:

15

- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid;
- (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;
- 25 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;

- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(butoxycarbonyl)amino]propanoic acid;
- 10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid; or
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid, or pharmaceutical salts thereof.
- 20 12. A compound of Claim 1 wherein G is 1,4,5,6-tetrahydropyrimidyl and R₄ is NHCONHR₉.
 - 13. A compound of Claim 1 which is:
- 25 (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(hexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid;
- (2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(1-adamantylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 40 (2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

-128-

- (2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-5 benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy}-benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid;
- 10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1.4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid
- 25 (2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1.4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid; or
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid or pharmaceutical salts thereof.
 - 14. A compound of Claim 1 wherein G is 1,4,5,6-tetrahydropyrimidyl and R₄ is NHCOR₉.
- 35 15. A compound of Claim 1 which is:
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid;
- 40 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-(isobutyrylamino)propanoic acid;
 - (2S)-2-(hexanoylamino)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-(pentanoylamino)propanoic acid;
- (2S)-2-[(3.3-dimethylbutanoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-[(cyclohexylcarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrirnidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid;
- 10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid;
 - (2S)-2-[(2-cyclohexylacetyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid;
 - (2S)-2-[(2-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 25 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methylbenzoyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid;
 - (2S)-2-[(4-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid;
- 40 (2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-[(2-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

- (2S)-2-[(4-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-[(2,3-dimethylbenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid; or
 - (2S)-2-[(3-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid or pharmaceutical salts thereof.
- 10 16. A compound of Claim 1 wherein G is pyrimidin-2-yl and R₄ is NHCO₂R₉.
 - 17. A compound of Claim 1 which is:
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(phenoxycarbonyl)amino]propanoic acid;
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyphenoxy)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;
- 30 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-([2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(4-nitrobenzyl)oxy]carbonyl}amino)propanoic acid;
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

-131-

- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methylphenoxy)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;
- 10 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;
- (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid; or
 - (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid or pharmaceutical salts thereof.
- 25 18. A compound of Claim 1 wherein G is pyrimidin-2-yl and R₄ is NHCONH₉.
 - 19. A compound of Claim 1 which is:

15

- (2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoyl}amino)propanoic acid;
 - (2S)-2-{[(tert-butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 35 (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(2-ethylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

25

- (2S)-2-{[(2,4-dichloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 5 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 20 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethyl)anilino]carbonyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid;
- (2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(4-fluoroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy|benzoyl}amino)propanoic acid:
- 35 (2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-({[4-(ethoxycarbonyl)anilino]carbonyl}amino)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid;

- (2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 5 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid; or
 - (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octylamino)carbonyl]amino}propanoic acid or pharmaceutical salts thereof.

- 20. A compound of Claim 1 wherein G is 4,5-dihydro-1H-imidazolyl and R $_4$ is NHCO₂R₉.
- 15 21. A compound of Claim 1 which is:
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- 20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(ethoxycarbonyl)amino]propanoic acid;

25

- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid;
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- 35 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;

- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(hexyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;

25

- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
- 5 (2S)-2-[(butoxycarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid;
 - 22. A compound of Claim 1 wherein G is 4,5-dihydro-1H-imidazolyl and R₄ is NHCONHR₉.
- 15 23. A compound of Claim I which is:
 - (2S)-2-{[(butylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- 20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(hexylamino)carbonyl]amino}propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(allylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-2-{[(benzylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- 35 3-({4-{2-(2,5-dihydro-1H-imidazol-4-ylamino)ethoxy}-2-hydroxybenzoyl)amino)-N-({[(1S, 2R)-2-phenylcyclopropyl]amino)carbonyl)alanine;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid;
 - (2S)-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid; or

- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid or pharmaceutical salts thereof.
- 5 24. A compound of Claim 1 wherein G is 4,5-dihydro-1H-imidazolyl and R₄ is NHCOR₉.
 - 25. A compound of Claim 1 which is:

25

40

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(isobutyrylamino)propanoic acid;

(2S)-2-(butyrylamino)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}arnino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(hexanoylamino)propanoic acid;

20 (2S)-3-([4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pentanoylamino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3,3-dimethylbutanoyl)amino]propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid;

(2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pent-4-ynoylamino)propanoic acid;

35 (2S)-2-[(cyclohexylcarbonyl)amino]-3-([4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid;

(2S)-2-[(2-cyclohexylacetyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

- (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid;
- 5 (2S)-2-[(2-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy}-2-hydroxybenzoyl}amino)-2-[(2-methylbenzoyl)amino]propanoic acid;
- 10 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2-methoxybenzoyl)amino]propanoic acid;
- (2S)-2-[(4-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(4-methylbenzoyl)amino]propanoic acid;
- 20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(4-methoxybenzoyl)amino]propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy}-2-hydroxybenzoyl}amino)-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid:
 - (2S)-2-[(2-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- (2S)-2-[(4-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,3-dimethylbenzoyl)amino)propanoic acid; or
- 35 (2S)-2-[(3-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid or pharmaceutical salts thereof.
- 26. A compound of Claim 1 wherein G is 3,4,5,6-tetrahydro-2H-azepinyl and R₄ is NHCO₂R₉.
 - 27. A compound of Claim 1 which is:
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

- (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;
- 5 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;
- (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid:
 - (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 20 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid:
 - (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;
- 35 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid; or
- (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 28. A compound of Claim 1 wherein G is NH₂C(NH)- and R₄ is NHCO₂R₅.

25

20

- 29. A compound of Claim 1 which is:
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid;
- 15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid;
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;
- 30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-40 {[([1,1'-biphenyl]-2-ylmethoxy)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(4-bromobenzyl)oxy]carbonyl}amino)propanoic acid;

20

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(4-fluorobenzyl)oxy]carbonyl}amino)propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(2-bromobenzyl)oxy]carbonyl}amino)propanoic acid; or
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[({[4-(trifluoromethyl)benzyl]oxy}carbonyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 30. A compound of Claim 1 wherein G is NH₂(NH)- and R₄ is NHCONHR₉.
 - 31. A compound of Claim 1 which is:
- 15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-toluidinocarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-chloroanilino)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2-bromoanilino)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[([1,1'-biphenyl]-2-ylamino)carbonyl]amino}propanoic acid;
- 30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-toluidinocarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-chloroanilino)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(4-fluoroanilino)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]-amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(cyclohexylamino)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzylamino)carbonyl]amino}propanoic acid;
- 10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(octylamino)carbonyl]amino}propanoic acid;
 - $(2S)-3-\{[4-(2-\{[amino(imino)methyl]amino\}ethoxy)-2-hydroxybenzoyl]amino\}-2-\{[(4-methoxyanilino)carbonyl]amino\}propanoic acid; or$
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(anilinocarbonyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 32. A compound of Claim 1 wherein G is NH₂(NH)- and R₄ is NHCOR₉.
 - 33. A compound of Claim 1 which is:
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]-amino}-2-(isobutyrylamino)propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-30 (butyrylamino)propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(hexanoylamino)propanoic acid;
- 35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pentanoylamino)propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3,3-dimethylbutanoyl)amino]propanoic acid;
- 40
 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2{[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid;
- (2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pent-4-ynoylamino)propanoic acid;
- 5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(cyclohexylcarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-phenylacetyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-phenylpropanoyl)amino]propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-cyclohexylacetyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid;
- 20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-chlorobenzoyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methylbenzoyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxybenzoyl)amino]propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-chlorobenzoyl)amino]propanoic acid; (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methylbenzoyl)amino]propanoic acid:
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxybenzoyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(pyridin-3-ylcarbonyl)amino]propanoic acid;
- 40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isonicotinoylamino)propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid;

10

- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-bromobenzoyl)amino]propanoic acid;
- (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-bromobenzoyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,3-dimethylbenzoyl)amino]propanoic acid;
- 10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-chlorobenzoyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(benzoylamino)propanoic acid:
- 15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-ethylbenzoyl)amino]propanoic acid; or
 - (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-butoxybenzoyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 34. A compound of Claim 1 wherein G is R_8NHCO_- , R_8 is benzyl and R_4 is $NHCO_2R_9$.
 - 35. A compound of Claim 1 which is:

25

- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-30 [(methoxycarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid;
- 35 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid;
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid;
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[(benzylamino)carbonyl]-amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid;

- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;
- 5 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(octyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;
 - (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid; or
- 20 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isobutoxycarbonyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 36. A compound of Claim 1 wherein G is R_8NHCO , R_8 is pyridin-3yl methyl, and R_4 is $NHCO_2R_9$.
 - 37. A compound of Claim 1 which is:
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;
- (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;
- 40 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;
 - (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;

25

- (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;
 - (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- 10 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;
- (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid; or
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 38. A compound of Claim 1 wherein G is R_8NHCO and R_8 is pyridin-4yl and R_4 is $NHCO_2R_9$.
 - 39. A compound of Claim 1 which is:
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;
 - (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- 40 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;

25

- (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(prop-2-ynyloxy)carbonyl]amino}propanoic acid;
- 10 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid:
 - (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid:
 - (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid; or
- 25 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid or pharmaceutical salts thereof.
 - 40. A compound of Claim 1 which is:
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methylbenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methoxybenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(4-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- 40 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(4-{2-[({[4-(dimethylamino)benzyl]amino}-carbonyl)amino]ethoxy}-2-hydroxybenzoyl)amino]propanoic acid;
 - (2S)-3-[(4-{2-[({[4-(aminosulfonyl)benzyl]amino}carbonyl)amino]ethoxy}-2-hydroxybenzoyl)amino]-2-{[(benzyloxy)carbonyl]amino}propanoic acid;

30

- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2-hydroxy-4-{2-[({[4-(trifluoromethoxy)-benzyl]amino}carbonyl)amino]ethoxy}benzoyl)amino]propanoic acid;
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(2-methylbenzyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- 10 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2-bromobenzyl)-amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(2,4-dichlorobenzyl)amino]-carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
 - (2S)-3-({4-[2-({[(2-aminobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid: or
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-2-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid or pharmaceutical salts thereof.
 - 41. A compound of Claim 1 which is:
- 25 (2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid;
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid tert-butyl ester;
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(pyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid;
- 3-{2-Hydroxy-5-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxyl-benzoylamino)-3-phenyl-propionic acid ethyl ester;
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid 2-(2-tert-butoxycarbonylamino-ethoxy)-ethyl ester;
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid ethyl ester;
- (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[3-(pyrimidin-2-ylamino)-propoxy}-benzoylamino}-propionic acid;

- 3-{2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino}-3-phenyl-propionic acid;
- 5 (2S)-2-{Adamantan-1-yloxycarbonylamino}-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino)-propionic acid;
 - (2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid ethyl ester;
 - 3-{2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy)-benzoylamino)-3-phenyl-propionic acid ethyl ester;
- (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{2-hydroxy-4-[2-(1,4,5.6-tetrahydro-pyrimidin-2-ylamino)-ethoxyl]-benzoylamino}-propionic acid;
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid isopropyl ester;
- 20 (2S)-2-tert-Butoxycarbonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid; or
 - (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid or pharmaceutical salts thereof.

30

- 42. A compound of Claim 1, which is:
- 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester;
- 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid;
- 2(S)-Benzenesulfonylamino-3-[2-hydroxy- 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride;
- 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydrochloride;
- 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride;

- 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride;
- 3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride;
- 5 3-[4-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid hydrochloride;
 - 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester;
- 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-10 propanoic acid;
 - 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester dihydro-chloride;
 - 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid;
- 3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid ethyl ester dihydrochloride;
 - 3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid;
- 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester;
 - 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-phenyl-propanoic acid hydrochloride;
 - 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride;
- 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-phenyl-propanoic acid;

WO 99/52879 PCT/US99/08180

- 3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester;
- 3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]benzoylamino]-3-phenyl-propanoic acid;
- 3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride;
 - 3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]benzoylamino]-3-phenyl-propanoic;
- 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride:
 - 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid methyl ester;
 - 2(S)-Benzyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid;
- 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-methyl-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid; or

- 2-Amino-3-[2-hydroxy-4-[2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid dihydrochloride or pharmaceutical salts thereof.
- 43. A pharmaceutical composition comprising a compound of Claim 1 and at least one pharmaceutically acceptable carrier or excipient.
 - 44. A method of treating a mammal afflicted with a condition that is mediated by an integrin receptor which comprises administration to the mammal a compound of the formula:

WO 99/52879 PCT/US99/08180

$$R^1$$
 G^{-N}
 N
 R^2
 R^4
 R^5

wherein:

G is

5

10

15

$$H_2N$$
 H_2N
 R¹ and R² are independently, hydrogen, alkyl of 1 to 6 carbon atoms, mono or bicyclic aralkyl of 6 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

R³ is hydrogen, mono or bicyclic aryl of 6 to 10 carbon atoms, 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O;

R⁴ is hydrogen, NHR⁹, OR⁹, NHCO₂R⁹, NHCONHR⁹, NHCOR⁹ or NHSO₂R⁹; provided that R³ and R⁴ are not both hydrogen;

20 R⁵ is hydrogen, or alkyl of 1 to 6 carbon atoms, optionally substituted with a terminal group forming a prodrug;

R⁶ and R⁷ are hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or aralkoxy of 6 to 10 carbon atoms;

R⁸ and R⁹ are independently hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbons, alkynyl of 2 to 10 carbons, mono or polycycloalkyl of 3-10 carbon atoms, mono or bicyclic aryl of 6 to 10 carbon atoms, 6 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O, mono or bicyclic aralkyl of 7 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

- 45. The method of Claim 44 wherein the integrin receptor is a_vb₃.
- 46. The method of Claim 44 wherein the condition is cancer.
- 47. The method of Claim 46 wherein the cancer is associated with at least one of metastasis, angiogenesis, neovascularization and tumor growth.
- 15 48. The method of Claim 44 wherein the condition is benign tumor growth.
 - 49. The method of Claim 44 wherein the condition is neovascularization.
 - 50. The method of Claim 49 wherein neovascularization is associated with diabetic retinopathy, glaucoma, macular degeneration or blindness.
- 51. The method of Claim 49 wherein neovascularization is associated with rheumatoid arthritis.
 - 52. The method of Claim 44 wherein the condition is inflammation.
 - 53. The method of Claim 52 wherein the inflammation is associated with rheumatoid arthritis or psoriasis.
 - 54. The method of Claim 44 wherein the condition is restenosis.
- 25 55. The method of Claim 54 wherein restenosis is associated with at lease one of smooth muscle cell migration, smooth muscle cell proliferation, vascular endothelial cell migration and vascular endothelial cell proliferation.
 - 56. The method of Claim 44 wherein the condition is viral infection.

WO 99/52879

- 57. The method of Claim 56 wherein the viral infection is caused by an adenovirus.
- 58. The method of Claim 44 wherein the condition is characterized by bone resorption.
- 59. The method of Claim 58 wherein bone resorption is associated with
 osteoporosis, Paget's disease, hypercalcemia, osteopenia, hyperparathyroidism, periarticular erosions, and periodontal disease.

PCT/US 99/08180

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D239/12 C07D C07D407/12 C07D239/42 C07D2O7/22 C07D223/12 CO7C279/14 C07D213/81 C07D213/82 C07D307/68 C07C275/16 CO7D403/12 A61K31/505 A61K31/41 A61K31/155 A61K31/17 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) CO7D CO7C A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Υ WO 95 32710 A (MERCK &CO., INC,) 1-59 7 December 1995 (1995-12-07) cited in the application claims 1-25 Υ WO 95 13262 A (RHONE-POULENC RORER LTD.) 1-59 18 May 1995 (1995-05-18) cited in the application claims 1-47 Α WO 97 08145 A (G. D. SEARLE & CO.) 1-59 6 March 1997 (1997-03-06) cited in the application claims 1-58 A EP 0 820 988 A (HOECHST AG & GENENTECH. 1 - 59INC.) 28 January 1998 (1998-01-28) claims 1-10 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 29 July 1999 10/08/1999 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Herz, C

Intu .onal Application No PCT/US 99/08180

		PC1/US 99/08180			
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	EP 0 820 991 A (HOECHST AG & GENENTECH, INC.) 28 January 1998 (1998-01-28) claims 1-11	1-59			
1	EP 0 796 855 A (HOECHST AG) 24 September 1997 (1997-09-24) claims 1-8	1-59			
	WO 98 08840 A (MERCK & CO., INC.) 5 March 1998 (1998-03-05) claims 1-33	1-59			
					
:	·				
	·				

information on patent family members

Inti. Conel Application No PCT/US 99/08180

Potent deciment		1	Dublication			99/08180
cited	atent document d in search report		Publication date		Patent family member(s)	Publication date
WO	9532710	Α	07-12-1995	AU	701776 B	04-02-1999
				ΑU	2586895 A	21-12-1995
				CA	2190870 A	07-12-1995
				EΡ	0760658 A	12-03-1997
				JP	10501222 T	03-02-1998
				US	5741796 A	21-04-1998
WO	9513262	Α	18-05-1995	AT	171158 T	15-10-1998
				AU	8149894 A	29-05-1995
				CA	2176363 A	18-05-1995
				DE	69413414 D	22-10-1998
				DE	69413414 T	25-03-1999
				EP	0728128 A	28-08-1996
				ES	2123941 T	16-01-1999
				JP	9505043 T	20-05-1997
				ZA	9409035 A 	14-05-1996
WO	9708145	Α	06-03-1997	AU	702487 B	25-02-1999
				AU	7103996 A	19-03-1997
				CA CN	2230209 A 1201454 A	06-03-1997
				CZ	9800341 A	09-12-1998
				EP	0850221 A	16-09-1998 01-07-1998
				NO	98 0 817 A	24-04-1998
				NZ	318926 A	29-04-1999 29-04-1999
				PL	325312 A	20-07-1998
EP	820988	Α	28 - 01-1998	DE	19629817 A	29-01-1998
				ĀŪ	2941997 A	05-02-1998
				BR	9704071 A	29-12-1998
				CA	2211148 A	24-01-1998
				CN	1174836 A	04-03-1998
				CZ	9702344 A	18-03-1998
				HR	97 04 05 A	30-04-1998
				HU	9701265 A	28-05-1998
				JP	10114751 A	06-05-1998
				NO	973400 A	26-01-1998
				NZ	328387 A	28-01-1999
				PL	321253 A	02-02-1998
				SK	100797 A	08-07-1998
EP	820991	Α	28-01-1998	DE	19629816 A	29-01-1998
				AU	2941897 A	05-02-1998
				BR Ca	9704072 A	05-01-1999
				CZ	2211270 A 9702343 A	24-01-1998
				HR	9702343 A 970404 A	18-03-1998 30-04-1998
				HU	970404 A 9701264 A	28-05-1998
	•			JP	11043476 A	16-02-1999
				NO	973399 A	26-01-1998
				NZ	328388 A	28-07-1998
				PL	321254 A	02-02-1998
				SK	100597 A	04-02-1998
EP	796855	Α	24-09-1997	DE	19626701 A	08-01-1998
			·	DE	19635522 A	05-03-1998
					 11	
				ΑU	1638097 A	25-09-1997

Information on patent family members

Inte one Application No PCT/US 99/08180

Patent document cited in search report		Publication date		Patent family member(s)		Publication date	
EP 796855	A		CA	2199923	A	20-09-1997	
			· CZ	9700823	Α	17-12-1997	
			HR	970156	Α	30-04-1998	
			HU	9700602	Α	30-03-1998	
			JP	9255664	Α	30-09-1997	
			NO	971268	Α	22-09-1997	
			NZ	314433	Α	29-03-1999	
			PL	319071	Α	29-09-1997	
			SK	35097	Α	08-10-1997	
WO 9808840	A	05-03-1998	AU	4086597	Α	19-03-1998	

Form PCT/ISA/210 (patent family ennex) (July 1992)